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ABSTRACT: 
Background: Human Immunodeficiency Virus (HIV) is an epidemic in South Africa with a 
rise in AIDS-defining malignancies, particularly Non-Hodgkin Lymphoma (NHL). B-cell 
stimulatory markers have been implicated in the risk and development of HIV-associated 
NHL. The mechanisms of the pathogenesis of HIV-associated NHL have not been fully 
elucidated but include: B-cell hyperactivation mediated by the over production of cytokines 
as a consequence of reduced immunosurveillance associated with CD4+ T-cell deficiencies. 
AIM: This study aimed to investigate and quantify the expression of B-cell stimulatory 
biomarkers in plasma and determine their contribution to lymphomagenesis in an HIV 
positive South African cohort.  
Methods: Plasma samples from HIV positive patients with confirmed NHL and HIV 
positive patients without evidence of lymphoma were assessed for ten cytokines: Interleukin 
(IL) IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, granulocyte-macrophage colony stimulating 
factor (GM-CSF), interferon gamma (IFNγ ) and tumour necrosis factor alpha (TNFα), as 
well as two soluble factors, sCD23 and sCD30 by Luminex Technology and ELISA 
respectively. Peripheral blood mononuclear cells from a HIV positive patient with Burkitts 
lymphoma were used to establish an in vitro culture. 
Results: Cytokines IL-6, IL-8 and IL-10 concentrations (pg/ml) were significantly elevated 
in HIV positive patients with NHL compared to the HIV positive controls. Soluble factors 
CD23 and CD30 concentrations (U/ml) were also elevated in HIV positive patients with 
NHL. 
Conclusion: IL-6, IL-8 and IL-10 may play a key role in stimulating B-cell proliferation 
and lymphomagenesis. IL-6 and IL-8 are pleiotropic pro-inflammatory cytokines, and IL-10 
an anti-inflammatory and/or regulatory cytokine, that act as growth factors in a paracrine or 
autocrine manner for HIV-associated lymphoma cells.  
 
  
Page | vi  
 
ACKNOWLEDGEMENTS 
 
My sincerest gratitude to the following people: 
My supervisors Miss Catherine Worsley and Dr Elizabeth Mayne for their guidance and 
technical assistance.  
Haematology registrars and flow cytometry staff for their extended helping hand in this 
project. 
The University of the Witwatersrand, National Research Foundation and the National 
Health Laboratory Services Research trust for providing funding. 
To my mother for her unconditional love and support throughout my studying career, and 
Mekyle Williams for always lending an ear. Finally God, the Almighty for helping me 
persevere to complete this degree. 
  
Page | vii  
 
Table of Contents 
DECLARATION .................................................................................................................................. ii 
DEDICATION: .................................................................................................................................... iii 
PRESENTATIONS ARSISING FROM THIS STUDY ...................................................................... iv 
ACKNOWLEDGEMENTS ................................................................................................................. vi 
LIST OF FIGURES .............................................................................................................................. x 
LIST OF TABLES: ............................................................................................................................. xii 
ABBREVIATIONS: ...........................................................................................................................xiv 
CHAPTER 1.0 ...................................................................................................................................... 1 
INTRODUCTION ................................................................................................................................ 1 
1.1 Development and differentiation of B-cells .......................................................................... 1 
1.2.   The development of haematological lymphoid neoplasms ...................................................... 3 
1.3.   Incidence of HIV Associated Non-Hodgkin Lymphoma in Sub-Saharan Africa .................... 4 
1.4. HIV infection leads to an increased risk of lymphoma .............................................................. 5 
1.5. Subtypes of high grade B-cell NHL Subtypes seen in HIV positive individuals ...................... 6 
1.5.1 Burkitt Leukaemia/Lymphoma ............................................................................................ 6 
1.5.2. Diffuse Large B-cell Lymphoma, not otherwise specified (DLBCL, NOS) ...................... 7 
1.5.3. B-cell lymphoma unclassifiable with features intermediate between Burkitt and Diffuse 
Large B-cell Lymphoma ............................................................................................................... 8 
1.5.4. Other high grade lymphoma subtypes arising in HIV positive individuals ........................ 8 
1.6. Biomarkers: Definition and function in HIV-associated Non-Hodgkin Lymphoma ................. 9 
1.7. B-cell stimulatory molecules and their role in B-cell lymphomagenesis ................................ 11 
1.7.1. B-cell growth factors ........................................................................................................ 11 
1.7.2. Immunoregulatory cytokine IL-10 .................................................................................... 12 
1.7.3.Chemokines implicated in B-cell physiology and NHL development............................... 12 
1.7.4. Th1 cytokines .................................................................................................................... 13 
1.7.5.  Soluble factors CD23 and CD30 in lymphomagenesis .................................................... 14 
AIM & OBJECTIVES: ....................................................................................................................... 15 
CHAPTER 2.0 .................................................................................................................................... 16 
MATERIALS AND METHODS........................................................................................................ 16 
2.1. Ethics Statement ...................................................................................................................... 16 
2.2. Study Cohort and sample collection ........................................................................................ 16 
2.3. Initial characterization of HIV-associated high grade B-cell lymphomas ............................... 17 
2.4. Detection and quantification of cytokines ............................................................................... 17 
Page | viii  
 
2.5. Quantification of Stromal Derived Factor-1 alpha (SDF-1α) by Luminex Technology .......... 18 
2.6. Quantification of soluble factors sCD23 and sCD30 in plasma by Enzyme-linked 
Immunosorbent Assay (ELISA) ..................................................................................................... 19 
2.6.1.  sCD23 detection by ELISA ............................................................................................. 19 
2.6.2. sCD30 ELISA ................................................................................................................... 19 
2.7. Optimization of the in vitro cell culture of HIV associated NHL cases .................................. 20 
2.7.1. Cryopreservation and thawing of cells ............................................................................. 20 
2.8. Antibody titration ..................................................................................................................... 21 
2.9. Flow cytometry to determine the role of significant biomarkers in lymphomagenesis ........... 21 
2.10. Propidium Iodide Live/Dead staining .................................................................................... 22 
2.11. Instrument Calibration ........................................................................................................... 22 
2.12. Statistical Analysis ................................................................................................................. 22 
1. Statistical methods .............................................................................................................. 22 
2.    Luminex and ELISA Data Analysis ..................................................................................... 23 
3. Flow Cytometric Data Analysis .......................................................................................... 23 
4. Demographic Data .............................................................................................................. 23 
CHAPTER 3.0 .................................................................................................................................... 24 
RESULTS ........................................................................................................................................... 24 
3.1. Sample Collection of Study Cohort ......................................................................................... 24 
3.2. Initial characterization of HIV-associated high grade B-cell lymphomas ............................... 27 
3.3. Cytokine expression in HIV positive lymphoma patients ....................................................... 31 
3.3.1. Circulating levels of B-cell growth factors ....................................................................... 31 
3.3.2. Immunoregulatory cytokine levels were elevated in HIV-associated NHL ..................... 33 
3.3.3. Chemokines detected in plasma of HIV-associated NHL patients ................................... 34 
3.3.4. Pro-inflammatory cytokines measured in HIV-associated NHL ...................................... 35 
3.4.  Correlation between significant levels of cytokines expressed in HIV-associated NHL ....... 36 
3.5. Circulating levels of soluble factors sCD23 and CD30 in HIV-associated NHL .................... 37 
3.6.  In vitro cell culture of HIV-associated NHL .......................................................................... 38 
CHAPTER 4.0 .................................................................................................................................... 39 
DISCUSSION OF RESULTS ............................................................................................................ 39 
4.1. General Background ................................................................................................................ 39 
4.2. Epidemiology of the study cohort ............................................................................................ 40 
4.3. Circulating biomarkers elevated in HIV positive patients with NHL ...................................... 41 
4.4. Immunoregulatory cytokine IL-10 was significantly elevated in HIV-associated NHL ......... 42 
Page | ix  
 
4.5. Th1 cytokines were not implicated in HIV-associated NHL ................................................... 42 
4.6. IL-8, but not SDF-1α, was significantly elevated in HIV-associated NHL ............................. 43 
4.7. Correlations between cytokine levels of IL-6, IL-8 and IL-10 ................................................ 44 
4.8. Soluble factors exhibit an increased trend in HIV-associated NHL ........................................ 44 
4.9. Cell culture of HIV-associated NHL ....................................................................................... 45 
4.10. Other factors impacting the results of this study ................................................................... 46 
CHAPTER 5.0 .................................................................................................................................... 46 
LIMITATIONS AND SHORT COMINGS ....................................................................................... 46 
CHAPTER 6.0. ................................................................................................................................... 47 
CONCLUSION & OUTLOOK .......................................................................................................... 47 
APPENDIX A ..................................................................................................................................... 48 
APPENDIX B ..................................................................................................................................... 53 
APPENDIX C ..................................................................................................................................... 56 
APPENDIX D ..................................................................................................................................... 57 
APPENDIX E ..................................................................................................................................... 62 
APPENDIX F ..................................................................................................................................... 64 
APPENDIX G ..................................................................................................................................... 66 
REFERENCE LIST ............................................................................................................................ 69 
 
Page | x  
 
LIST OF FIGURES 
Chapter 1.0: Introduction 
Figure 1.1: Schematic representation of the development and differentiation                     2 
Of B-cells 
Figure 1.2: The 5-year prevalence of Non-Hodgkin lymphoma is not as    5 
high in Africa compared to other continents 
Figure 1.3: Microscopic representation of Burkitt Leukaemia/     6 
Lymphoma 
Figure 1.4: Representation of microscopic haematoxylin & eosin     7 
stains of Diffuse Large B-cell lymphoma 
Figure 1.5: Microscopic representation of a triple hit B-cell     8 
lymphoma unclassifiable with features intermediate between DLBCL and BL. 
 
Chapter 3.0: Results 
Figure 3.1: Flow cytometric Immunophenotyping diagnosis of    28 
normal polyclonal case 
Figure 3.2: Flow cytometric Immunophenotyping diagnosis of     29 
a high grade DLBCL case 
Figure 3.3: Immunophenotypic diagnosis of a high grade      30 
DLBCL case 
Figure 3.4: B-cell growth factors expressed in HIV positive     32 
patients with documented NHL 
Figure 3.5: Immunoregulatory cytokine expression was elevated    33 
 in HIV-associated NHL  
Figure 3.6: Circulating chemokine IL-8 was increased in HIV-    34 
associated NHL 
Figure 3.7: Circulating levels of SDF-1α in HIV associated NHL    36 
Figure 3.8: Soluble Factor expression in HIV-associated NHL    37 
Figure 3.9: Flow cytometric histograms of Propidium Iodide viability   38 
 Assay 
 
 
Page | xi  
 
Appendix A 
Figure 1: Printout of ethics clearance certificate      48 
Figure 2: Turnitin Report         49 
 
Appendix D 
Figure 3: CD19 PE Antibody Titration       57 
Figure 4: CD38 APC Antibody titration       58 
Figure 5: CD3 FITC Antibody titration       59 
Figure 6: CD4 PE Antibody titration       60 
Figure 7: CD8 AlexaFluor® 700 Antibody titration      61 
Appendix F 
Figure 8: Snapshot of the daily QC SPHERO Rainbow      64 
Single Peak calibration beads 
 
Apendix G 
Figure 9: Human 10-plex cytokine panel 5-parameter logistic     66 
standard curves 
Figure 10: Human 10-plex cytokine panel 5-parameter logistic     67 
standard curves 
Figure 11: sCD23 4-parameter logistic standard curve     68 
Figure 12:  sCD30 4-parameter logistic standard curve     68 
  
Page | xii  
 
LIST OF TABLES: 
Chapter 1.0: Introduction 
Table 1.1: Classification of lymphomas corresponding to the different    3 
stages of B-cell development and differentiation 
 
Chapter 3.0: Results 
Table 3.1: Characteristics of the cohort’s demographics     25 
Table 3.2: Characteristics of HIV-Associated NHL Subtypes    26 
 with location and CD4 count 
Table 3.3:  Pro-inflammatory cytokines and GM-CSF statistical     35 
data identified in HIV –associated NHL cases vs. HIV positive controls 
 
Appendix A 
Table 1:   A description of B-cell stimulatory molecules and there     50 
function in relation to B-cell lymphomas 
 
Appendix B 
Table 2: Human cytokine 10-plex panel: Cytokine analytes and    53 
 their respective standard concentrations 
Table 3: Human cytokine 10-plex panel reagent preparation    53 
 indicating the appropriate dilution factor and volumes 
Table 4: Standard concentrations of the SDF-1α Luminex     55 
 and ELISA assays 
Table 5: Reagent preparation including the dilution factor and     54 
volumes for sCD30 ELISA kit 
Table 6: Reagent preparation including the dilution factor and     54 
volumes for sCD23 EASIA ELISA kit 
 
Appendix D 
Table 7: Mean Fluorescence Intensity values for antibody     57 
 titration of CD19 PE 
Table 8: Mean Fluorescence Intensity values for antibody     58 
 titration of CD38 APC 
Page | xiii  
 
Table 9: Mean Fluorescent Intensity values for antibody      59 
titration of CD3 FITC 
Table 10: Mean Fluorescent Intensity values for antibody      60 
titration of CD4 PE 
Table 11: Mean Fluorescent Intensity values for antibody      61 
titration of CD8 Alexa Fluor® 700 
 
Appendix E 
Table 12: A comprehensive list of MAb panel used to perform    62 
 antibody titration and set-up of multi-colour compensation  
Table 13: Experimental layout for flow cytometry assay       62
      
 
  
Page | xiv  
 
ABBREVIATIONS: 
BCR   B-cell receptor 
Bcl6   B-cell CLL/lymphoma 6 
BL   Burkitts Leukaemia/ Lymphoma 
BMC   Bone marrow mononuclear cells 
CHB   Chris Hani Baragwanath Hospital 
CMJAH  Charlotte Maxeke Johannesburg Academic Hospital 
CNS   Central nervous system 
CRP   C-reactive protein 
DLBCL  Diffuse Large B-cell Lymphoma 
EBV   Epstein - Barr virus 
EDTA   Ethylenediaminetetraacetic acid 
ELISA   Enzyme linked Immunosorbent assay 
FLC   Free-light chains 
GIT    Gastrointestinal tract 
GM-CSF  Granulocyte-macrophage colony stimulating factor 
HAART  Highly active anti-retroviral therapy 
HHV-8  Human herpesvirus-8 
HIV   Human Immunodeficiency Virus 
HL    Hodgkin Lymphoma 
IFNγ   Interferon gamma 
Ig   Immunoglobulin 
IgH   Immunoglobulin heavy chain 
Page | xv  
 
IL   Interleukin 
KSHV   Kaposi’s sarcoma herpesvirus 
MAb   Monoclonal antibody 
NHL   Non-Hodgkin Lymphoma 
NHLS   National Health Laboratory Services 
PBMC   Peripheral blood mononuclear cells 
PEL   Primary effusion Lymphoma 
PI   Propidium Iodide 
PL   Plasmablastic Lymphoma 
QC   Quality Control 
RPMI   Roswell Park Memorial Institute 
sCD Antigen  Soluble CD Antigen 
SDF-1α  Stromal derived factor 1 alpha 
Th   T helper cells  
TMB   Tetrametylbenzidine 
TNFα   Tumour necrosis factor alpha 
WHO   World Health Organization 
 
 
 
 
 
 
Page | 1  
 
CHAPTER 1.0 
INTRODUCTION 
 
1.1 Development and differentiation of B-cells 
The adaptive immune response is divided into the cell-mediated (the T-cell response) and 
humoral responses (the antibody response mediated by B-cells) 
(1)
. During cell-mediated 
immunity, cytotoxic T-cells destroy intracellular pathogens. The humoral response involves 
the production of antibodies by B-cells under the control of CD4+ T cells 
(1, 2)
.  
B-cells develop in the bone marrow from pluripotent haematopoietic progenitor stem cells 
and migrate to secondary lymphoid organs for further maturation 
(3-5)
. The common lymphoid 
progenitor or haematopoietic stem cell gives rise to a Pro-B cell. During this stage, there is 
germline rearrangement of the immunoglobulin heavy chain (IgH) gene of the B-cell receptor 
(4, 6)
 
(7, 8)
. The Pro-B cell matures to a Pre-B cell and the rearrangement of the kappa and 
lambda light chain genes are initiated. Should the rearrangements result in the formation of a 
functional B-cell receptor, the B-cell will be released from the bone marrow as a mature B 
cell (Figure 1.1) 
(3, 4)
.
 
B-cell receptors are secreted as immunoglobulins or antibodies which 
bind to antigens from pathogens. They have a number of functions including pathogen 
opsonisation, neutralisation, activation of complement and stimulation of natural killer cell 
killing (antibody-dependent cellular cytotoxicity) in order to illicit a specific immune 
response 
(2, 9)
. 
(4, 10)
.
 
Mature B-cells undergo further maturation and antibody diversification by  two processes; 
somatic hypermutation and isotype class switch recombination 
(11)
. This usually occurs in the 
germinal centre of the peripheral lymphoid tissue 
(4)
 and is mediated by additional signals 
from CD4+ T cells (T helper cells). And/or by direct cell-cell contact or through the secretion 
of cytokines such as IL-4 and IL-5. During somatic hypermutation, point mutations 
accumulate in the V region of both the heavy and light chain genes 
(12-14)
. Isotype switching 
allows cells to switch the class of antibody from IgM which is first produced to IgG, A or E.  
Somatic hypermutation increases the affinity of antibodies for particular antigens during the 
late primary or secondary immune response.  
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Mature activated B-cells terminally differentiate into antibody secreting plasma cells and 
memory B cells post germinal centre (Figure 1.1) 
(1, 4)
.  
Defects in B-cell activation results in abnormal antibody production and failure to switch 
from the low affinity antibody IgM to IgG, A or E. The ability to negatively select self-
reactive B-cells is consequently affected 
(15, 16)
 .  
 
 
 
 
 
 
 
 
 
 
  
Figure 1.1: Schematic representation of the development and differentiation of B-cells. 
Immature B-cells develop in the bone marrow from progenitor B-cells. Naïve mature B-cells 
migrate to the germinal centre in the peripheral lymphoid tissue where they differentiate into 
antibody secreting plasma cells and memory B cells [Taken from Jaffe et al, 2008. WHO 
Classification of Tumours of haematological and lymphoid tissues]. 
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1.2.   The development of haematological lymphoid neoplasms 
Lymphomas are the most common haematopoietic malignancies of lymphoid origin 
(17, 18)
. 
They frequently present as tumours in lymphoid tissues, including lymph nodes, mucosa-
associated lymphoid tissue, spleen and bone marrow but can proliferate and disseminate to 
other soft tissues and organs 
(18)
. B-cell lymphomas can be classified according to the stage of 
B-cell maturation or differentiation in which they arise (Table 1.1) 
(1, 19)
. B-cell lymphomas 
are classified as either Hodgkin (HL) or Non-Hodgkin lymphomas (NHL) and according to 
their clinical growth behaviour as low-, intermediate or high-grade (aggressive) lymphomas 
(17, 19-21)
.  
 
Table 1.1: Classification of lymphomas corresponding to the different stages of B-cell 
development and differentiation [Adapted from Weigert et al, 2012 and Jaffe et al, 2008] 
 
 
 
 
 
 
Stage of Normal B-cell development/ Cell 
Type 
Corresponding malignancy 
 Pre/Pro B-cell Precursor B-cell leukaemia/ lymphoma 
 Naïve mature B-cell/ Pre Germinal centre 
B-cell 
Mantle cell lymphoma 
 Germinal centre neoplasms 
 Centroblast 
Hodgkin’s lymphoma 
Diffuse Large B-cell lymphoma 
Burkitts lymphoma 
 Centrocyte Follicular lymphoma 
 Post germinal centre Plasmacytoma 
DLBCL 
Plasmablastic DLBCL 
Marginal zone lymphoma 
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1.3.   Incidence of HIV Associated Non-Hodgkin Lymphoma in Sub-Saharan Africa 
Infection rates of human immunodeficiency virus (HIV) in South Africa are high with an 
estimated disease burden of 6.4 million infected individuals and 2.4 million deaths as 
indicated by the UNAIDS 2014 HIV statistics in South Africa report 
(22)
. High grade B-cell 
NHL is an AIDS-defining condition 
(23-25) 
with a reported increased risk of development in 
HIV positive individuals compared with the general HIV negative population 
(26-28)
.
 
Conversely, according to the GLOBOCAN 5 year estimated incidence and prevalence report, 
there is a lower prevalence of NHL in Africa (5.9%) compared with developed countries 
(Figure 1.2) 
(29)
. Studies conducted between 2007 and 2009 in the Gauteng province of South 
Africa, however, noted an increase in the prevalence of aggressive high grade B-cell 
lymphomas (from 64% in 2004-2006 to 82%). Of the patients diagnosed with high grade 
lymphoma, 90% also tested positive for HIV infection. These high grade lymphomas 
included; Diffuse large B-cell lymphoma (DLBCL), DLBCL plasmablastic variant, Burkitt 
leukaemia/lymphoma (BL), HL and plasma cell dyscrasias 
(30, 31)
. A 16% increase (from 24 to 
40% in the last decade) in the incidence of NHL was reported in a study conducted at Chris 
Hani Baragwanath (CHB) hospital between the period 2003-2012 
(28)
. Data from the Western 
Cape Province in South Africa also reported increased numbers of HIV-related lymphoma 
(from 5-37%) between the periods of 2002-2009 
(32)
. DLBCL followed by BL was the most 
frequent diagnosis 
(32)
. Data on HIV associated malignancies are scarcely documented 
suggesting that the reported incidence of NHL in South Africa may be lower than the actual 
incidence. This may be a reflection of under recognition and failure to diagnose and/or 
document some cases 
(31, 32). 
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Figure 1.2: The 5-year prevalence of Non-Hodgkin lymphoma is not as high in Africa 
compared to other continents. [Adapted from GLOBOCAN Estimated Cancer Report, 
2012]. 
 
1.4. HIV infection leads to an increased risk of lymphoma 
The World Health Organization (WHO) classifies HIV-associated lymphomas into three 
groups: lymphomas occurring in immunocompetent patients, lymphomas occurring in HIV-
positive patients and lymphomas occurring in patients with other forms of 
immunosuppression 
(33-36)
.  In HIV positive individuals, approximately ~70-90% of 
lymphomas are aggressive high grade B-cell malignancies 
(27, 37, 38)
, and  include BL, DLBCL, 
Plasmablastic lymphoma (PL) of the oral cavity, Primary effusion lymphoma (PEL) and its 
solid variants and large cell lymphoma arising in Human herpesvirus-8 (HHV8) associated 
multicentric Castleman’s disease (34, 39-41). The WHO has recently assigned a provisional 
category of B-Cell Lymphoma unclassifiable, with features intermediate between DLBCL and 
BL. This intermediate group share morphological, immunophenotypic and 
molecular/cytogenetic features with both DLBCL and BL which make the diagnostic 
distinction difficult. There has been an increase in the diagnosis of highly aggressive B-cell 
lymphoma intermediate group 
(42)
. 
31% 
30% 
24% 
7% 
6% 
2% 
GLOBOCCAN 2012 5-YEAR ESTIMATED 
INCIDENCE AND PREVALANCE REPORT 
OF NHL 
Asia
Europe
Northern America
Latin America and
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1.5. Subtypes of high grade B-cell NHL Subtypes seen in HIV positive individuals 
1.5.1 Burkitt Leukaemia/Lymphoma  
Burkitt Leukaemia/Lymphoma is a mature lymphoproliferative disorder and is a high-grade 
aggressive NHL characterised by a high proliferation rate 
(43)
. BL is also seen in 
immunocompetent individuals, predominantly children in the endemic BL areas where it 
often presents as a jaw mass. In adults, it is one of the most common AIDS-defining 
malignancies 
(44-47)
.  The disease in HIV-infected individuals clinically presents with a bulky 
tumourigenic mass localized in the lymph nodes and bone marrow but may include other 
extra-nodal sites such as the central nervous system (CNS) 
(44, 45)
. BL comprises 
monomorphic medium sized B-cells which contain densely-packed chromatin and prominent 
nucleoli. Intermingled macrophages and/or phagocytes containing debris of apoptotic cells 
give the illusion of a starry sky pattern (Figure 1.3) 
(48-50)
. The translocation of the c-MYC 
gene located on chromosome 8 to the immunoglobulin locus (most commonly the heavy 
chain locus on chromosome 14) , is a distinct genetic characteristic of BL 
(43, 51)
. BL presents 
with a mature B-cell immunophenotype expressing CD19 and CD20 as well as CD10 
reflecting the germinal centre cell of origin. The cells generally show light chain restriction 
and PCR reactions for antibody rearrangements are monoclonal 
(46, 52)
.  The high proliferation 
rate is indicated by the cell turnover marker, Ki-67, which shows an index approaching 100% 
(44, 49)
.  
 
 
 
  
 
 
 
Figure 1.3: A) Microscopic haematoxylin and eosin stain of a Burkitt 
Leukaemia/Lymphoma resembling a starry sky pattern. [Taken from the NHLS/ CSIR 
Database] 
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1.5.2. Diffuse Large B-cell Lymphoma, not otherwise specified (DLBCL, NOS) 
Diffuse Large B-cell lymphoma, not otherwise specified is the second commonest AIDS-
defining malignancy 
(53, 54)
. Clinical manifestations include an enlarging tumour mass 
primarily involving the gastrointestinal tract (GIT), (Figure 1.4), but can include other extra-
nodal sites such as the CNS, oral cavity and salivary glands, breast and nose 
(55-57)
. Patients 
often present with B-cell lymphoma symptoms, including night sweats, unintended weight 
loss and fevers, reflecting the aggressive nature of this tumour 
(36, 55)
. Morphologically, the 
cells are larger with prominent nucleoli and fewer mitoses. Variants of HIV related DLBCL 
are morphologically categorised as centroblastic, immunoblastic and/or anaplastic 
(48, 58)
. 
The most common chromosomal translocation seen in DLBCL is that of the B-cell 
CLL/lymphoma 6 (Bcl6) gene (3q27) which occurs in approximately ~25-40% of patients, and 
may be IgG or non-IgG related 
(43, 59)
. Bcl6 modulates B-cell responses to the growth factor, 
IL-4 and is also associated with germinal centre B-cells 
(60, 61)
. Other genetic anomalies 
associated with HIV-associated DLBCL include mutations  of various proto-oncogenes such 
as PAX5, PIM1 and MYC 
(62)
. DLBCL show features similar to BL with B-cell markers, CD19 
and CD20 and light chain restriction. In addition, DLBCL may express the germinal centre 
marker, CD10. Typically, it shows a lower proliferative index (a Ki67 of less than 90%) 
although this may be higher in HIV-associated tumours 
(43, 44, 49, 51)
. 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Representation of microscopic haematoxylin & eosin stains of Diffuse Large 
B-cell lymphoma. A) Histological representation of a HIV-associated DLBCL extra-nodal 
case in the GIT. B) Shows a polymorphic centroblastic lymphoma, 40x magnification. [Taken 
from Romero-Guadarrama et al, 2012.Open J of Path; Grogg et al, 2007. J. Clin. Path] 
A 
 
B 
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1.5.3. B-cell lymphoma unclassifiable with features intermediate between Burkitt and 
Diffuse Large B-cell Lymphoma 
B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL is a 
provisional category assigned by the WHO to aggressive high grade lymphomas displaying a 
variable spectrum of morphologic, immunophenotypic and molecular/cytogenetic features 
resembling and characteristic of BL and DLBCL 
(42)
. These tumours show immunophenotypic 
features suggestive of a germinal centre cell of origin and often show MYC Ig gene 
translocations. 
(43, 48, 51)
. Morphologically, the cells often resemble BL cells and the 
proliferative index can be high. 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Microscopic representation of a triple hit B-cell lymphoma unclassifiable 
with features intermediate between DLBCL and BL. [Taken from the NHLS and CSIR 
Database]. 
 
1.5.4. Other high grade lymphoma subtypes arising in HIV positive individuals 
Primary effusion lymphoma, plasmablastic variant of DLBCL and large cell lymphoma 
arising in HHV8 associated multicentric Castleman’s disease, are also associated with 
development in HIV infection. 
PEL occurs less frequently than the fore a mentioned lymphomas, accounting for 4-5% of all 
HIV-associated NHL 
(27, 63)
. Pre-existing or co-infection with other oncogenic gamma 
herpesviruses predominantly HHV8 and/or Karposi’s sarcoma herpesvirus (KSHV) as well as 
EBV are concomitant infections in patients with HIV-associated PEL 
(43, 63)
. The disease 
generally manifests in body cavities such as the pericardium, pleural and peritoneum 
(64)
.  
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Immunophenotypically, PEL are void of the expression of most B-cell lineage markers but 
express other markers usually associated with plasma cell activation and differentiation. 
These include CD138, MUM1 and CD71 to mention a few 
(65-67)
.  
 
Plasmablastic lymphoma is a subtype of DLBCL as described by the WHO 
(27, 42)
.  PL occurs 
commonly in the oral cavity and jaw of HIV positive individuals as well as in 
immunocompetent HIV negative individuals 
(68, 69)
. The lymphoma arises from activated B-
cells or a plasmablast that has already undergone affinity maturation by somatic 
hypermutation and class switching. Morphologically it has similar features to BL and 
DLCBL.  These cells express plasma cell markers CD38, CD138, Ki67, BLIMP-1 ( plasma 
cell differentiation  marker) and MUM/IRF4 
(68, 70)
. 
 
Large cell lymphoma arising in HHV8 associated multicentric Castleman’s disease is usually 
EBV negative, but is positive for Kaposi’ sarcoma herpesvirus (71). These lymphomas arise 
from naïve B-cells and lack immunoglobulin gene mutations 
(71,72)
. Germinotropic 
lymphoproliferative disorder is a variant of the latter where germinal centre B-cells are co-
infected with gamma herpesviridae 
(40, 69)
.  These lymphomas will not be further discussed in 
this study as they were not included in the study cohort.  
 
1.6. Biomarkers: Definition and function in HIV-associated Non-Hodgkin Lymphoma 
New methods are continuously being pursued to improve the diagnosis and monitoring of 
disease. Biomarkers can be measured and investigated as potential indicators of biological, 
pathogenic and pharmacological processes and/or responses to therapeutic strategies 
(73, 74)
 
and are  used to diagnose and prognosticate in a number of diseases including cancer, 
infectious diseases and autoimmune diseases. These biomarkers can be proteins (chemokines, 
growth factors, cytokines or hormones) or complex carbohydrates and lipids 
(38)
, and can be 
detected in a vast number of specimen types such as serum, plasma, whole blood and/or cell 
culture supernatant 
(20)
. Cancer-associated biomarkers may be increased  as a direct result of 
malignancy or as an indirect effect of the malignant processes 
(20)
. Identification of novel and 
existing biomarkers in cancer patients could provide insight into prognosis and could be 
useful in guiding treatment 
(20, 75, 76)
.  
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The exact mechanisms of B-cell oncogenesis in HIV are uncertain. Infection with HIV causes 
severe defects in cell-mediated immunity, with decreased CD4+ T-cell counts as well as 
impaired cytotoxic T-cell killing associated with dysregulated immunosurveillance against 
tumours and virally infected cells, consequently disturbing the homeostasis of B-cells 
(77-79)
.  
HIV also targets key molecules of the immunological synapse (like CD4) which results in 
incomplete signalling, thereby altering the terminal differentiation and affinity maturation 
processes of B-cells 
(80, 81)
. 
 
Polyclonal B-cell activation is also characteristic of HIV infection which is often associated 
with a number of non-specific B-cell activation features 
(82)
. These include non-specific 
hypergammaglobulinaemia (an increase in Ig secreting cells), the presence of auto-reactive 
antibodies as well as and a number of antibody mediated autoimmune phenomena like 
immune-mediated thrombocytopaenia 
(23, 81-83)
.  There is persistent infection and failure to 
clear a number of B-cell tropic viruses which are associated with B-cell transformation, such 
as oncogenic  gamma-herpesviridae, EBV and KSHV 
(71)
. Viral proteins from both of these 
viruses have been directly implicated in HIV associated lymphomagenesis and represent a 
diagnostic criteria for conditions like primary effusion lymphoma 
(72)
.
 
Lastly, evidence exists 
that there is direct antigenic stimulation of B-cell by the virus itself mediated by antigenic 
components incorporated into the viral envelope 
(27, 84, 85)
.  
 
Aberrant expression of B-cell stimulatory biomarkers in HIV-associated NHL has been 
previously studied 
(38, 76, 83, 86)
. These studies found that serum levels of several B-cell 
stimulatory cytokines and immune markers associated with B-cell activation are elevated 
prior to development and diagnosis of HIV-associated NHL. These include cytokines 
interleukin-6 (IL-6), IL-10 and tumour necrosis factor alpha (TNFα), soluble factors CD23, 
CD27, CD30, C reactive protein (CRP), chemokine CXCL13 and  immunoglobulin free light 
chains (FLC) 
(1, 40, 41(83, 86)
.  
 
Expression of these biomarkers in HIV positive patients with NHL in low and middle income 
countries, like South Africa, have been poorly documented. There are likely to be differences 
to biomarkers reported in patients from Europe and the USA, considering a higher burden of 
chronic infectious diseases (excluding HIV) and relatively advanced stage of 
immunodeficiency seen in South African patients, as well as the late presentation of patients 
to oncology services 
(31, 87)
.  
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1.7. B-cell stimulatory molecules and their role in B-cell lymphomagenesis 
Cytokines are a heterogeneous group of low molecular weight, extremely potent, secreted 
proteins that act as messengers of the immune system that exert effects upon a target cell 
(38, 
88)
. These molecules have multiple roles in immune cell function and development, and exert 
their functions in either a paracrine manner to modulate the activity of surrounding or nearby 
cells, or in an autocrine fashion affecting the cell responsible for the production of the 
cytokine 
(89)
. The following biomarkers will be investigated in this study based on their 
involvement in the development of HIV-associated NHL, as reported in the literature: B-cell 
growth factors IL-4, IL-5 and IL-6. The immunoregulatory and/or anti-inflammatory cytokine 
IL-10, chemokines (CXCL8) IL-8, stromal derived factor 1 alpha (SDF-1α), pro-
inflammatory cytokines IL-1β, and IL-2, TNFα and interferon gamma (IFNγ). In addition, 
this study will consider soluble factors associated with B-cells namely sCD23 and sCD30. 
 
1.7.1. B-cell growth factors 
IL-4 is a multi-functional T helper (Th) cell 2 cytokine and growth factor of mature B-cells 
(9, 
90)
. IL-4 also induces its effects on various targets such as haematopoietic cells, tumour and 
endothelial cells 
(91)
. Along with co-stimulatory molecules CD40 ligand (CD40L) and 
lipopolysaccharide (LPS), IL-4 has the capacity to induce B-cell proliferation, differentiation 
and antibody secretion 
(92, 93)
. It is predominantly responsible for the class switching of 
antibody secreting B-cells to IgE 
(94, 95)
. T follicular helper cells (TFH) located in the germinal 
centre, also produces IL-4. The germinal centre is where most NHL tends to develop 
indicating a role in lymphomagenesis 
(84)
. 
 
IL-5 is another cytokine produce by Th2 as well as mast cells 
(92)
. It acts on various targets 
binding to its receptor to induce cell survival and differentiation of B-cells as well as 
eosinophil’s and basophils (96, 97). IL-5 also stimulates the maturation of CD40 activated B-
cells and IgG1 secretion in B-cells stimulated with LPS 
(92, 93)
. 
 
The pleiotrophic pro-inflammatory cytokine IL-6 is a potent autocrine B-cell growth factor 
(83, 
98, 99)
. IL-6 has been extensively studied for its role in both HIV infection and HIV related 
NHL 
(100, 101)
. Increased IL-6 levels are well-documented in HIV positive patients and show a 
strong correlation with mortality in patients with low CD4+ T cell counts 
(102)
. IL-6 may 
reflect the chronic and recurrent inflammatory process underlying chronic HIV infection and 
many other disease states 
(103)
.   
Page | 12  
 
It is a non-redundant cytokine associated with terminal B-cell differentiation, specifically 
plasma cell differentiation, and assists in antibody production subsequently enhancing the 
development of lymphoma 
(94)
. The role of IL-6 in B-cell lymphomagenesis is well 
documented in chronic viral infections and IL-6 mimetic agents are associated with infection 
with agents such as KSHV 
(104, 105)
. Numerous studies have shown that IL-6 levels are 
elevated in HIV infection facilitating  its replication cycle as well as significantly elevated  
preceding the development of HIV associated NHL 
(106-108)
. 
 
1.7.2. Immunoregulatory cytokine IL-10 
IL-10 is an anti-inflammatory and/or regulatory cytokine produced by regulatory T cells 
(107)
. 
It mainly functions as an immunosuppressive cytokine converting the immune system from a 
Th1 pro-inflammatory state to an anti-inflammatory state 
(9)
. IL-10 also induces the 
production of cytotoxic T-cells and the expression of IFNγ thereby promoting tumour killing 
(109)
.  
Normal and malignant B-cells produce and respond to IL-10, thereby promoting B-cell 
growth and lymphomagenesis in an autocrine manner 
(98, 99)
. In addition, it also promotes the 
differentiation of B-cells into plasma cells that secrete IgM, IgG and IgA 
(94, 110, 111)
. A single 
nucleotide polymorphism (SNP) within the promoter region of IL-10 with the genotype ( -592 
C/C) has been associated with development of HIV related lymphoma  
(79)
. Pre-diagnostic 
serum levels of IL-10 have also been shown to be elevated in patients with HIV associated 
NHL 
(83, 108, 112)
. 
 
1.7.3.Chemokines implicated in B-cell physiology and NHL development 
Chemokines are chemoattractrant cytokines that are responsible for trafficking of a number of 
immunologically active cells including B-cells and T-cells. They have an important 
homeostatic function in lymphocyte maturation and movement, and are up-regulated in 
response to inflammatory processes and result in cell cycle arrest 
(113, 114)
. 
 
IL-8 is a chemokine of the CXC family and function as an activator and chemokine attractant 
of neutrophils 
(115)
. IL-8 is also a pluripotent pro-inflammatory cytokine that has been reported 
to be related to the progression of tumours, prognosis and survival in various types of cancers 
(116)
. In the tumour microenvironment, IL-8 is known for its angiogenic properties attracting 
neutrophils and macrophages to tumour site which may produce other cytokines and growth 
factors further promoting tumour growth and angiogenesis 
(115, 117)
.  
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It is also produced by tumour cells and acts in a paracrine manner on nearby cells in the 
tumour microenvironment to exert its function and support tumour growth, proliferation and 
metastasis 
(115)
. Studies examining the relationship between IL-8 and NHL development have 
demonstrated that IL-8 was elevated in conjunction with creatinine in the urine of patients 
with NHL 
(116)
. Other studies showed that IL-8 was expressed in several AIDS-NHL cell lines 
and was also significantly expressed in patients with NHL with or without HIV infection 
(118-
120)
. 
Another cytokine, SDF-1 or more commonly referred to as CXCL12, functions as a 
chemoattractant that homes haematopoietic stem cells, specifically B-cell and its precurosrs,  
to the bone marrow microenviroment 
(113, 114, 121)
. In HIV infection, SDF-1 mediates the 
hyperproliferation of B-cells and shares a co-receptor or ligand with HIV, CXCR4, which has 
been shown to be highly expressed in hematological malignancies 
(121, 122)
.  
Individuals with a single nucleotide polymorphism within SDF-1 (SDF1-3'A)  have an 
increased risk of HIV associated NHL 
(121, 122)
. 
 
1.7.4. Th1 cytokines 
IL-1β, IL-2, IFNγ and TNFα are a collective group of pro-inflammatory cytokines. IL-1β is 
produced by activated macrophages and monocytes and mediates inflammation in conjunction 
with other mediators of inflammation affecting nearly all cell types 
(123)
.  
 
IL-1β is produced by activated macrophages and monocytes and mediates inflammation in 
conjunction with other mediators of inflammation affecting nearly all cell types 
(123)
.The role 
of IL-1β in HIV-associated NHL is not known and has not been fully described. In HIV 
infection, however, IL-1β induces the expression of HIV-1 in U1 cells, a chronically infected 
cell line and is speculated to play a role in the pathogenesis of HIV along with IL-6 
(107, 124)
. 
 
IL-2 is produced by Th1 cells but is also a haematopoietic growth factor involved in the 
differentiation of naïve T-cells into Th1 cells 
(125-127)
. IL-2 receptors are also located on 
normal B-cell and in malignant B-cell lines such as BL, chronic lymphocytic leukaemia and 
hairy cell leukaemia 
(125, 128)
. In B-cell development, IL-2 enhances the differentiation of and 
Ig production by activated B-cell with other cytokines 
(94, 129, 130)
.  
 
T helper cells 1 secrete a number of B-cell stimulatory cytokines such as IFNγ and TNFα 
which skew the adaptive immune response from a B-cell predominant humoral response to a 
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cell-mediated response 
(9, 107)
. IFNγ  is a type II interferon that has both anti-viral and anti-
tumour properties as well as protecting the immune system against  intracellular pathogens 
(131)
. It primarily differentiates naïve T-cells into Th1 cells (along with IL-2) and aids in 
tumour surveillance by inducing the activity of cytotoxic lymphocytes. In addition, it also has 
the ability to induce class switching of B-cells 
(132, 133)
. Studies have shown that IFNγ is 
increased in patients with HIV-associated NHL compared to HIV positive controls 
(120)
.  
 
TNFα exerts its function indirectly on B-cells in an autocrine manner by augmenting the 
secretion of various cytokines (such as IL-6, IL-8 and IL-10), which in turn enhance B-cell 
functioning 
(134-137)
. Increased serum levels of TNFα have also been associated with HIV-1 
induced polyclonal B-cell activation as well as IL-4 induced antibody production., suggesting 
a possible role in lymphomagenesis (134, 138).  Its pathogenic role in HIV-1 infection 
involves activation of nuclear factor ĸB (NFĸB), stimulating apoptosis of T-cells and 
reducing HIV-1 viremia 
(137)
.   
 
1.7.5.  Soluble factors CD23 and CD30 in lymphomagenesis 
Other markers have also been associated with B-cell activation and NHL development. 
Soluble CD23 is a low affinity receptor for IgE and is expressed on resting mature B-cells as a 
differentiation and/or early activation marker. sCD23 is cleaved from the cell surface of 
activated B-cells 
(139, 140)
, and has been linked to various other disease states in persons with 
B-cell hyperactivation and augmented  humoral immunity, allergies  as well as elevated IgE 
levels 
(141-143)
. sCD30 is a member of the TNF receptor superfamily which are markers of B- 
and T-cell activation 
(84)
. sCD30 is a known marker of chronic B-cell stimulation which may 
be involved in B-cell proliferation that could lead to genetic error accumulations and possibly 
cause lymphoma 
(144-146)
. 
 
A comprehensive list of B-cell stimulatory molecules associated with B-cell malignancies in 
HIV is appended. (See Appendix A, Table 2). Although, it is clear that these molecules may 
contribute to the development and subsequent growth of malignant lymphomas, the actual 
role of individual cytokines and stimulatory molecules has not been fully elucidated 
(27, 84, 85)
. 
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AIM & OBJECTIVES: 
The aim of this study was to detect and quantify specific biological biomarkers in the plasma 
of patients with HIV-associated high grade B-cell lymphoma and investigate their 
contribution to lymphomagenesis within a South African population/setting. 
Objectives 
1. To determine the expression of cytokines, chemokines and soluble factors in the 
plasma of patients with HIV-associated high grade B-cell lymphoma using the Bio-Rad 
Luminex xMAP™ Technology cytokine/chemokine panels and ELISA soluble factor 
kits. 
2. To investigate the effects of various cytokines on a lymphoma cell culture by 
measuring markers of activation CD38+, proliferation Ki-67 and/or ploidy and 
Annexin V-FITC apoptotic assay, by immunophenotyping and flow cytometry. 
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CHAPTER 2.0 
MATERIALS AND METHODS  
 
2.1. Ethics Statement 
This study was approved by the Medical Human Research Ethics Committee (HREC) of the 
University of the Witwatersrand and provided with the clearance number HREC M140395 
(Appendix A). This project was conducted in accordance with the guidelines of the ethics 
committee. 
 
2.2. Study Cohort and sample collection 
This study used residual peripheral blood samples collected in ethylenediaminetetraacetic acid 
(EDTA) tubes from HIV positive patients diagnosed with high-grade mature B-cell NHL by 
histology or by immunophenotyping (n=36). The B-cell NHL subtypes included in this study 
were Burkitt Leukaemia/lymphoma, Diffuse Large B-cell Lymphoma and DLBCL not 
otherwise specified with features intermediate between Burkitt and Diffuse Large B-cell 
lymphoma.  Samples from patients with PEL, PL and large cell lymphoma arising in HHV8 
multicentric Castlemen’s disease were not included or further studied. Samples were collected 
between 2013 and 2015 referred from the Wits Academic Hospital Complex (Chris Hani 
Baragwanath Hospital, Helen Joseph Hospital and Charlotte Maxeke Johannesburg Academic 
Hospital) referred to the immunophenotyping laboratory at Charlotte Maxeke Johannesburg 
Academic hospital (CMJAH) (National Health Laboratory Service). All adult patients 
between the ages of 18-80 years with confirmed HIV infection and diagnosis of NHL with 
sufficient residual sample for testing were originally included. Clinical data including 
diagnosis, age, gender, CD4 counts, and viral loads were collected from the NHLS TrakCare 
Lab database system. A small number of samples (n=4) had later to be excluded because of 
co-existing confounding diseases, specifically co-infection with Mycobacterium tuberculosis. 
Patients with NHL were matched by age (5 years) and gender to HIV-positive patients with 
no laboratory evidence of B-cell NHL (n=32).Peripheral blood was centrifuged at 3500 
revolutions per minute (rpm) for 15 minutes to separate plasma. Plasma was stored for all 
patients at -80⁰C until further use. 
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2.3. Initial characterization of HIV-associated high grade B-cell lymphomas  
The  diagnosis of HIV-associated high grade mature B-cell lymphoproliferative disorders was 
made by histology and subtyping was confirmed immunophenotypically (by flow cytometry 
or by immunohistochemistry) on an appropriate sample according to the WHO classification 
of haematological lymphoid malignancies 
(34)
.  The following markers were used to 
characterize and identify patients with HIV-associated high grade B-cell lymphomas: B-cell 
lineage markers CD19, 20, germinal center marker CD10, and FMC7 which is an epitope for 
CD20 
(46, 55)
. Clonality was determined by kappa or lambda Ig light chain restrictions or by 
PCR analysis of IgH gene rearrangements 
(48)
. If indicated, additional markers were added 
including CD38, CD138 and BLIMP-1 to indicate plasma cell differentiation 
(68, 70)
. In all 
cases, samples were obtained before patient’s commenced chemotherapy. 
 
2.4. Detection and quantification of cytokines  
Luminex multiplex assays are fluorescent magnetic bead based immunoassays that allows for 
the quantifiable detection of multiple markers within a single sample, simultaneously 
(147)
. 
The principle of the method is based on the concept of the sandwich ELISA where the antigen 
in question present in the sample is sandwiched between two antibodies conjugated to beads 
(148, 149)
. The concentration of the protein is proportional to the amount of streptavidin-RPE 
fluorescence detected. 
Experiments were conducted on plasma of HIV-positive patients diagnosed with high grade 
B-cell NHL (n=32) and HIV positive individuals without overt evidence of lymphoma 
(n=32). The cytokines assessed were selected based on the relevant literature and the human 
cytokine 10-plex panel (Invitrogen, Life Technologies Corporation, USA) was selected as the 
most appropriate to measure the relevant cytokines. The following analytes were measured: 
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, granulocyte-macrophage colony stimulating factor 
(GM-CSF), interferon gamma (IFNγ) and TNFα. All standards and plasma samples were set 
up in duplicate and reagents as well as were allowed to come to room temperature before 
proceeding with experiments. All standards, plasma samples and buffers (wash solution, 
antibody mixes, and streptavidin-RPE) were diluted with the appropriate diluent prior to the 
experiment (see Appendix B). Standards and plasma samples were incubated with conjugated 
capture antibodies beads in a 96 well plate for 2 hours at room temperature in the dark on a 
rotating platform. After incubation, the plate was washed with wash solution to remove 
excess unbound antibody.  
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A secondary biotinylated detector antibody was added to all wells and the samples were 
incubated for an additional 1 hour. The wash step was repeated post incubation to remove 
excess biotinylated antibody. Conjugated Streptavidin-RPE, was added to all wells and the 
samples were incubated for a further 30 minutes 
(150, 151)
. The beads were resuspended in wash 
solution and standards and samples were acquired using the Luminex xMAP™ technology 
(Bio-Rad Laboratories Inc., USA) and xPONENT 3.1 acquisition software (Luminex 
Corporation, Austin, Texas). 
 
2.5. Quantification of Stromal Derived Factor-1 alpha (SDF-1α) by Luminex Technology 
Recent literature has suggested that SDF-1α levels were significantly increased in the plasma 
of HIV positive patients with NHL 
(113)
. Patients with residual sample were therefore tested 
subsequent to the cytokine analysis for SDF-1α levels. Unfortunately, only 20 patients had 
sufficient residual samples for assessment. An SDF-1α simplex kit was selected which uses 
similar principles to the cytokine kit but utilises magnetic beads.   
A magnetic 96-well plate was coated with magnetic SDF-1α antibody beads and allowed to 
rest for 2 minutes on a magnetic hand held washer for the accumulation of the beads before 
the liquid was discarded. Standards and plasma samples were incubated for 2 hours at room 
temperature in the dark on a rotating platform. The liquid was then discarded and the 
magnetic wash step repeated twice to remove unbound antibody. Detection antibody was 
added to all wells and incubated for another 30 minutes. The wash step was repeated twice 
and streptavidin-PE was added to all wells followed by a final incubation period of 30 
minutes. The beads were resuspended in reading buffer and acquired using the Luminex 
xMAP™ technology (Bio-Rad Laboratories Inc., USA) and xPONENT 3.1 acquisition 
software USA).  
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2.6. Quantification of soluble factors sCD23 and sCD30 in plasma by Enzyme-linked 
Immunosorbent Assay (ELISA)  
Previous studies have demonstrated increased serum levels of sCD23 and sCD30 in HIV 
positive individuals who develop lymphoma and NHL several months before diagnosis 
(84, 
152)
. This may show utility for early diagnosis and monitoring of response.  To determine 
levels in this study cohort, human soluble CD23 (sCD23) EASIA (BioSource Europe S.A., 
Belgium) and CD30 (sCD30) ELISA kits (Invitrogen, Life Technologies Corporations, USA) 
were used to perform the relevant assays.  
All standards, controls and plasma samples were set up in duplicate by vertical alignment as 
suggested per manufacturer’s protocol. Microwell strips (96) pre-coated with capture 
monoclonal antibodies against sCD23 and sCD30 were provided with the each individual kit. 
In addition, lyophilized standards (1-6) and lyophilized controls (1 and 2) in human plasma 
with preservatives were provided with the sCD23 kit (see Appendix B for control and 
standard concentrations). 
 
2.6.1.  sCD23 detection by ELISA 
The sCD23 assay is a chromogenic ELISA which utilises tetrametylbenzidine (TMB) to allow 
visualisation. Standards, controls and patient samples were incubated with anti-sCD23 
conjugate for 2 hours at room temperature on a rotating platform. Post incubation, the plate 
was washed three times with wash solution. TMB was added to all wells and incubated for 
another 30 minutes. Stop solution was added to all wells when the highest standard developed 
a determined degree of chromogenicity. The absorbance was read at 450nm 
(153) 
on the 
NEXGEN FOUR fully automated ELISA machine and Open Lab® Adaltis software (Adaltis, 
Italy). Additional filters of 620nm and 405nm were included for plastic interference and over-
range filter respectively.  
 
2.6.2. sCD30 ELISA 
 Plasma samples and standards were incubated with diluted horseradish peroxidase (HRP) 
conjugate for 3 hours at room temperature on a rotating platform. All wells were emptied and 
washed three times to remove excess unbound antibody. TMB substrate solution was added to 
all wells and incubated for an additional 10 minutes. Stop solution was added to all wells 
when the highest standard concentration developed a dark blue colour  
(154)
.  
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The absorbance was read at 450nm on the NEXGEN FOUR fully automated ELISA machine 
and Open Lab® Adaltis software (Adaltis, Italy). Additional filters of 620nm and 405nm were 
included for reference wavelengths, with a range of 610-650nm as acceptable).  
 
2.7. Optimization of the in vitro cell culture of HIV associated NHL cases 
2.7.1. Cryopreservation and thawing of cells 
PBMC or (BMC) cells isolated via Ficoll-Histopaque density gradient centrifugation method 
were stored in cell culture freezing media (Millipore Corporation, USA) at -80⁰C until further 
use. The cells were thawed in complete culture media composed of Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with L-glutamine and Sodium hydrogen 
carbonate (NaHCO3) (Sigma- Aldrich, Steinheim) with 5% fetal bovine serum (FBS) 
(Highveld Biological, SA) and 1% penicillin/ streptomycin (Gibco Life Technologies, USA). 
The cells were thawed in a water bath at 37⁰C, resuspended in culture media and centrifuged 
at 3000 rpm to wash off  residual freezing medium. The total numbers of cells were counted 
and the viability was checked under an inverted light microscope (Alltion®(Wuzhou) 
Co.,Ltd. China) using the Neubauer haemocytometer counter chamber (Hausser Scientific, 
USA) and trypan blue exclusion dye (Sigma-Aldrich, Steinheim) 
(155, 156)
. Trypan blue 
exclusion dye was used to determine the number of live and dead cells, as well as cell 
viability. Live cells were impermeable to the dye because of their intact plasma membrane 
and remained unstained, whereas dead cells absorbed the dye into the cytoplasm as a result of 
the loss of their membranes and were stained blue 
(157, 158)
.  
 
The volume of culture media was adjusted in order to resuspend the cells at a concentration of 
1 x 10
6 
cells/ml (see Appendix C for calculations). The cells were then incubated for 24 hours 
at 37⁰C with 5% CO2 until confluent  
(155)
. Cells were then seeded at a concentration of 1 x 
10
6
cells/ml and treated with 200-1000 pg/ml of recombinant human IL-6 and further 
incubated for 2 hours at 37⁰C with 5% CO2 in air. 
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2.8. Antibody titration 
Antibody titration was performed on various MAb to determine the optimal concentration or 
volume that would produce the highest and lowest fluorescent intensity of the positive and 
negative populations of interest respectively, while simultaneously reducing the amount of 
background signal or noise and non-specific binding of the antibody to the population of 
interest 
(159)
. Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral 
blood collected in EDTA tubes by Ficoll-histopaque density gradient-centrifugation. MAb 
(Appendix D) were incubated with PBMCs for 15 minutes in the dark at room temperature. 
An unstained tube containing cells only was also included.  
Unbound antibody was then washed with PBS and the cells were resuspended in PBS and 
were acquired on the LSRII flow cytometer (BD-Biosciences, USA) using BD FACSDiva 
v6.1 acquisition software (BD-Biosciences, USA). 
 
2.9. Flow cytometry to determine the role of significant biomarkers in lymphomagenesis 
Flow cytometry was performed to investigate the effects of various biomarkers, selected from 
the previous Luminex and ELISA assays, on the cultured lymphoma cells. Parameters 
measured included; CD38 which determined the percentage of activated tumour cells, Ki-67 
which is a marker of proliferation, and propidium iodide (PI) which measured the ratio of 
live-to-dead cells. All samples used had tumour burdens in excess of 90% of cells on initial 
flow cytometric analysis and it was not considered necessary to add either B-cell or T-cell 
discriminatory markers. 
Cells were harvested and resupended in culture media. Cells were added to the appropriate 
tubes with MAb ( Appendix E) and incubated for 30 minutes in the dark at 2 - 8°C.The cells 
were washed twice with cell staining buffer to wash off residual culture media (BioLegend, 
USA). The cells were then resuspended in cell staining buffer and acquired on the LSR II 
Flow cytometer using the BD FACSDiva v6.1 software (BD-Biosciences, USA). A minimum 
of 100000 events were recorded. 
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2.10. Propidium Iodide Live/Dead staining 
Propidium Iodide is a viability dye which stains the nucleus of a cell by intercalating between 
the   nucleic acids of double stranded DNA. Viable cells have intact cell membranes and are 
impermeable to the dye, whereas dead cells are permeable to the dye 
(160)
. Cultured PBMCs 
were harvested and washed in PBS and resuspended in cell staining buffer. Cells were stained 
with 10 µl of PI followed by an incubation period in the dark at room temperature. The cells 
were then acquired on the LSRII Flow cytometer using BD FACSDiva v6.1 software (BD-
Biosciences, USA) with a minimum of 1 million events recorded. An unstained control was 
used to set the voltages for the FSC and SSC scatter dot plots in acquisition mode. Analysis 
was performed using FlowJo gating software (FlowJo v9.2, ©Tree Star Inc.). 
 
2.11. Instrument Calibration 
Please see Appendix F for calibration of the LSRII Flow cytometer and Bio-Rad 
Luminex200. 
 
2.12. Statistical Analysis 
1. Statistical methods 
Normality or frequency distribution was measured using Shapiro Wilk normality test and 
computed using GraphPad prism (GraphPad Prism 5™, San Diego, California, USA). If the 
data were normally distributed the mean, standard deviation and Pearson’s correlation was 
used. Non-parametric parameters and measures of association such as the median, range and 
Spearman’s rank correlation respectively, were computed if the data were not normally 
distributed. HIV-associated NHL and HIV positive controls without lymphoma data were 
computed and compared to one another using the non-parametric Mann-Whitney test. Where 
the data were normally distributed, parametric unpaired student’s t-test was computed. All 
box and whisker plots are representative of the minimum and maximum values or range 
depicted by the bars and/or whiskers, 25
th
 and 75
th
 percentiles represented by the body and/or 
box itself and the median, as shown by the horizontal line within the box. P values of * = p < 
0.05; **= p < 0.001 and ***= p<0.0001 were considered to be statistically significant. 
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2. Luminex and ELISA Data Analysis 
The mean concentration and mean fluorescent intensities (MFI) were collected for all analytes 
acquired on the Luminex xMAP™ technology (Bio-Rad Laboratories Inc., USA). The 
average optical density (450nm) and plasma concentration (U/ml) were recorded for both 
sCD23 and sCD30 ELISA assays. Cytokine plasma concentrations (pg/ml) were calculated 
and extrapolated from a 5-point logistic standard curve for all samples (See Appendix G ). 
Soluble factor concentrations (U/ml) were calculated and extrapolated from a 4-point logistic 
standard curve for all samples (See Appendix G). 
3. Flow Cytometric Data Analysis 
Data from the flow cytometric analysis was analysed using FlowJo software (FlowJo v9.2, 
©Tree Star Inc.). Populations of interest were gated along a forward (FSC) vs. side scatter 
(SSC) dot plot using BD FACSDiva Software v6.1 (BD Biosciences, USA). Propidium Iodide 
plots were represented as histograms in the linear scale. The non-viable cells were also gated. 
The (MFIs) and/or geometric means were recorded for the antibody titrations curve using 
FlowJo software and plotted against the respective volumes on a xy graph using Microsoft 
Excel.  
The highest point or plateau area on the graph indicated the optimal concentration or amount 
of antibody to use for optimal fluorescent intensity and cell positivity for experimentation 
(Appendix F). 
4. Demographic Data 
The median was measured and computed for demographic data such as the age (range ±5 
years), CD4+ T cell (x10
6
L) counts and HIV viral loads (copies/ml) were data was available.  
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CHAPTER 3.0 
RESULTS 
 
3.1. Sample Collection of Study Cohort 
Residual blood was collected from HIV positive patients with confirmed NHL (n=36) and 
compared with HIV positive age- and gender-matched controls without any evidence of 
lymphoma (n=32). Of these HIV-positive NHL cases, 19 were diagnosed with  DLBCL, 5 
with BL, 4 had a diagnosis of unclassifiable lymphoma with features intermediate between 
DLBCL and BL and 4 cases were not classified by subtype 
(36, 42)
. None of the patients 
assessed had documented plasmablastic variant lymphoma, primary effusion lymphoma or 
HHV8 and therefore was not examined.  The majority of the HIV-associated NHL tumours 
were initially localized in extra-nodal sites. Diffuse large B-cell lymphoma tumours were 
localized to the GIT and head and neck masses and to nodal sites including the cervical and 
axillary nodes. Burkitt lymphoma cases presented mainly in the CNS and the axillary. The 
intermediate group, demonstrated lymphoma masses mainly in the pelvic or cervical nodes. 
Primary tumour location could not be determined in n=13 cases. In many of these cases, the 
patients presented with widely disseminated disease or leukaemia. The aforementioned are 
described in Table 3.1 which outlines the site or location of the tumour per NHL subtype, 
while Table 3.2 depicts demographic information for all patients including age, CD4 count (x 
10
6
L) and HIV viral load (copies/ml).  
 
In HIV-associated NHL cases, the median age was 39 years and the CD4+ T cell count was 
significantly lower compared to the HIV positive controls (median 101 vs. 356.77 x 10
6
L, 
p<0.0001). The median CD4+T counts of patients DLBCL (131 x 10
6
L) were slightly higher 
(p= 0.8699) than patients diagnosed with BL (41 x 10
6
L), intermediate lymphoma (86 x 10
6
L) 
and NHL cases not specified (79 x 10
6
L). The majority of the study cohort (n=23) and 
controls (n=25) had a viral load below the limit of detection. Of those patients who had 
detectable viral loads, the median viral load was higher in HIV-associated NHL cases 
compared with controls (401 275 vs. 73.50 copies/ml).  
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Table 3.1: Characteristics of HIV-Associated NHL Subtypes with location and CD4 
count  
 
 
HIV-associated  NHL subtypes Site of lymphoma Median CD4 count 
(X10
6
L) 
 
 
Burkitt Leukaemia/Lymphoma 
3 disseminated  
1 CNS 
1 Axillary mass 
41 
 
Diffuse large B-cell Lymphoma 
Unknown primary site (n=6) 
Head and neck masses (non-
nodal) 
Nasopharyngeal masses (n=2) 
 Para nasal mass  (n=1) 
Posterior nasal space (n=1) 
Gastrointestinal tumour 
Small intestine (n=1) 
Colon (n=1) 
Nodal sites 
Sub-mandibular and cervical 
nodes (n=3) 
1 Cervical node 
1Inguinal node (n=1) 
3 Axillary nodes (n=3) 
131 
 
B-Cell Lymphoma unclassifiable, 
with features intermediate 
between diffuse large B-cell 
lymphoma (DBCL) and Burkitt 
lymphoma (BL) 
Pelvic mass (n=1) 
Mediastinal mass (n=1) 
Unknown primary site (n=1) 
1 Cervical node (n=1) 
86 
 
Not specified 
Unknown primary site (n=3) 
1 cervical node (n=1) 
79 
Page | 26  
 
Table 3.2: Characteristics of the cohort  
Parameter HIV-associated B-cell 
NHL 
HIV positive controls 
Sample size (n) 32 32 
 
Age (years) range 
 
18-58 
 
19-61 
 
Median age (5 years) 
 
39.00 
 
40.50 
Average age± Std deviation 39.42±9.354 39.37±11.61 
 
Gender 
 
15 F;17 M 
 
15 F;17 M 
 
CD4 Count (X10
6
L) Range 
 
13-747  
 
69-830 
CD4 Count (X10
6
L) Median 101 356.77 
Average CD4 Count± Std 
deviation  
 
159±195.3 
 
378.27±206.07 
HIV Viral load (copies/ml) 
Median 
401 275 (n= 9) 73.50 (n=7) 
 
Treatment status (n)   
On HAART n= 11 
 
32 
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3.2. Initial characterization of HIV-associated high grade B-cell lymphomas  
Flow cytometric plots of a normal B-cell population and a high grade DLBCL NOS case are 
presented in Figure 3.1 below.  Lymphocytes were defined by their forward and side scatter 
characteristics. The B-cells were identified by expression of the pan-B-cell marker CD19. 
Clonality was determined by the ratio of expression of kappa to lambda light chains (with a 
ratio of 1:1 to 3:1 considered normal). DLBCL cells were identified by their size (larger than 
normal lymphocytes), the monoclonal expression of either kappa or lambda light chains and 
by the expression of B-cell markers. The expression of CD20 and the epitope FMC-7 with 
surface IgM expression was used to assess maturity and CD10 expression was considered an 
immunophenotypic indication in mature cells of germinal centre origin. A representative 
scatter plot of a DLBCL tumour is shown in Figure 3.2 and a polyclonal B-cell population in 
Figure 3.3.  The normal lymphocytic population highlighted in green on the FSC vs. SSC in 
Figure 3.1. 
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Figure 3.1: Flow cytometric immunophenotypic diagnosis of a normal polyclonal case. 
A) FSC vs. SSC dot plots illustrates lymphocytes, B) The cells demonstrate a normal 
polyclonal light chain ratio (anti-Kappa (FITC) on the x-axis) Lambda (PE) on the y-axis). C) 
CD5 (APC) vs. CD19 (PerCP) shows CD5+ B cells and D) CD19+ B-cells. 
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Figure 3.2: Flow cytometric immunophenotypic diagnosis of a high grade DLBCL case. 
A) The cells are larger than typical lymphocytes B) the cells demonstrate lambda light chain 
restriction [Kappa (FITC) vs. Lambda]  C) and D) the cells express both the germinal centre 
marker, CD10, and positivity for the pan-B cell marker CD19. 
 
 
 
 
 
 
 
Kappa FITC 
La
m
b
d
a 
P
E 
B 
C 
CD19 PerCP 
C
D
1
0
 A
P
C
 
Si
d
e
 s
ca
tt
e
r 
A 
Forward scatter 
CD19 PerCP 
Si
d
e
 s
ca
tt
e
r 
D 
Page | 30  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Immunophenotypic diagnosis of a high grade DLBCL case. Cells show B) 
maturation and bright CD20 expression (FMC7 (FITC)) and express the germinal centre 
marker CD10 (PE), C) and D) bright CD20 expression (PerCP). 
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3.3. Cytokine expression in HIV positive lymphoma patients 
This study aimed to examine the circulating cytokine expression in the plasma of HIV 
positive NHL patients and was compared to HIV positive patients with no evidence of NHL 
as it was hypothesized that these levels would differ between the two groups. Plasma samples 
were assessed for 10 cytokine analytes namely: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, 
IFNγ, GM-CSF and TNFα as well as SDF-1α using the Luminex analyser with xPONENT 3.1 
software. Cytokine analytes will be discussed in functional groups; B-cell growth factors, 
anti-inflammatory and/or immunoregulatory cytokines, chemokines and pro-inflammatory 
cytokines. 
 
3.3.1. Circulating levels of B-cell growth factors 
IL-4, -5 and -6 were the B-cell growth factors measured in this study. IL-6 is a pleiotropic 
cytokine that is involved in the terminal differentiation of B cells and aids in antibody 
production 
(83, 99)
. The median IL-6 concentration was significantly elevated in HIV positive 
patients with NHL compared with HIV positive controls without evidence of lymphoma 
(median concentration, 16.70 vs. 8.892 pg/ml respectively, p<0.0001) (Figure 3.4). IL-4 is a 
B-cell haematopoietic growth factor and facilitates proliferation in the presence of co-
stimulatory molecules such as CD40 or lipopolysaccharides (LPS) 
(95)
, whereas IL-5 directly 
promotes the differentiation and proliferation of B-cells 
(92)
. In this study it was observed that 
the median IL-4 concentration levels were slightly higher in HIV positive patients compared 
with controls, however these results were not statistically significant (median concentrations 
67.46 vs. 42.29 pg/ml respectively, p= 0.4211). No differences were noted between HIV-
positive patients with NHL and controls for IL-5 (median concentrations 18.52 vs. 18.43 
pg/ml respectively, p= 0.1642) (Figure 3.4). 
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Figure 3.4: B-cell growth factors expressed in HIV positive patients with documented 
NHL. A) IL-6 median concentration was significantly elevated in HIV-associated NHL cases 
(median 16.70 pg/ml) compared to HIV positive controls (median 8.892 pg/ml), p<0.0001. B) 
IL-4 median concentration was slightly elevated in HIV-associated cases (median 67.46 
pg/ml) compared with controls (median 42.29 pg/ml) but was not significant. C) No 
statistically differences in the median concentration levels of IL-5 between HIV-associated 
NHL cases and controls (median 18.52 vs. 18.43 pg/ml respectively). 
B C 
A 
0
20
40
60
80
***
IL-6
C
o
n
c
e
n
tr
a
ti
o
n
p
g
/m
l
0
20
40
60
80
100
IL-4
C
o
n
c
e
n
tr
a
ti
o
n
p
g
/m
l
18
19
20
21
HIV ASSOCIATED NHL
HIV+ CONTROLS
IL-5
C
o
n
c
e
n
tr
a
ti
o
n
p
g
/m
l
Page | 33  
 
3.3.2. Immunoregulatory cytokine levels were elevated in HIV-associated NHL 
IL-10 is an anti-inflammatory and/or regulatory cytokine which suppresses tumour specific 
responses and also serves as a growth factor for non-malignant and malignant B-cells  in an 
autocrine manner thus contributing to lymphomagenesis  
(98, 99)
. It was observed that  the 
median IL-10 plasma concentration was significantly elevated in HIV positive patients with 
NHL compared to HIV positive controls without evidence of lymphoma (median 
concentration, 42.46 vs. 21.34 pg/ml respectively, p= 0.0010) (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Immunoregulatory cytokine expression was elevated in HIV-associated 
NHL. IL-10 median concentration was significantly higher in HIV positive individuals with 
NHL (median 42.46 pg/ml) compared to HIV positive controls without lymphoma (median 
21.34 pg/ml), p= 0.0010.  
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3.3.3. Chemokines detected in plasma of HIV-associated NHL patients 
IL-8 is a pluripotent chemokine of the CXC family and angiogenic cytokine that has been 
reported to be related to the progression of tumours, prognosis and survival in various types of 
cancers 
(116)
. IL-8 median concentrations were significantly elevated in plasma of HIV 
positive patients with NHL compared with HIV positive controls (median concentration, 
262.1 vs. 82.43 pg/ml respectively, p= 0.0098 (Figure 3.6). 
 
SDF-1 is a chemoattractant for homing haematopoietic stem cells, specifically the B-cell and 
its precursors, to the bone marrow microenviroment 
(114)
. Differences in the medians of the 
plasma concentrations of SDF-1α were noted and elevated in HIV positive patients with NHL 
cases compared to HIV positive controls without lymphoma. These results were not, however, 
statistically significant (median concentration, 347.1 vs. 318.1 pg/ml respectively, p= 0.3513) 
(Figure 3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Circulating chemokine IL-8 was increased in HIV-associated NHL. A) IL-8 
was significantly elevated in HIV positive individuals with NHL (median 262.1 pg/ml) 
compared to HIV positive controls (median 82.43 pg/ml), p = 0.0098. B) Differences SDF-1α 
in medians were noted between HIV positive patients with NHL (median 347.1 pg/ml) and 
controls (318.1 pg/ml) but were significant, p=0.3514. 
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3.3.4. Pro-inflammatory cytokines measured in HIV-associated NHL 
Pro-inflammatory cytokines were assayed in HIV positive individuals with NHL (Table 3.3). 
Each of these cytokines is associated with aspects of B-cell development. IL-2, along with 
other cytokines, assists with the differentiation of activated B cells 
(94). TNFα provides co-
stimulus for the differentiation of B-cells induced by CD40L and IL-4. IFNγ promotes the 
survival and differentiation of B-cell 
(94)
 and GM-CSF is an essential haematopoietic growth 
factor and immune modulator 
(161)
. No statistical differences were noted between the median 
concentrations of HIV-associated NHL cases compared to HIV positive controls without 
evidence of lymphoma for the cytokines levels of IL-1β, IL-2, IFNγ, TNFα and GM-CSF.  
The median concentrations are tabulated below for each analyte. 
 
Table 3.3: Pro-inflammatory cytokines and GM-CSF statistical data identified in HIV-
associated NHL cases vs. HIV positive controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokine Median concentration (HIV positive NHL 
cases vs. HIV positive controls without 
lymphoma) 
IL-1β 15.84 vs. 15.42, p = 0.8676 
IL-2 18.93 vs. 16.48 pg/ml, p= 0.5732 
TNFα 15.71 vs. 14.02 pg/ml, p= 0.9667 
IFNγ 23.21 vs. 21.62 pg/ml, p = 0.9267 
GM-CSF 43.75 vs. 29.21 pg/ml, p = 0.6150 
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  3.4.  Correlation between significant levels of cytokines expressed in HIV-associated NHL 
IL-6, IL-8 and IL-10 were found to be significantly elevated in HIV-associated NHL when 
compared to HIV positive controls. We determined whether there was any correlation 
between these cytokines in HIV positive patients with NHL No significant correlation was 
noted between cytokine concentration levels of IL-6 and IL-8 (Spearman’s correlation, 
r=0.01128, p= 0.9564), or between IL-8 and IL-10 (Spearman’s correlation, r= -0.2278, p = 
0.2630) (Figure 3.7).The latter cytokine concentrations also showed a negative correlation. 
Cytokine concentration levels of IL-6 and IL-10, however, were significantly correlated with 
one another (Spearman’s correlation, r= 0.6280, p<0.0002) (Figure 3.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: IL-6, -8 and -10 Correlations. IL-6 and IL-10 showed significant correlation, 
whereas no correlation was shown between IL-6 and IL-8, or IL-8 and IL-10. A) IL-6 vs. IL-8 
(r=0.01128, p = 0.9564), B) IL-8 vs. IL-10 ( r= -0.2278, p = 0.2630). and C) IL-6 vs. IL-10 
(r= 0.6280, p<0.0002). 
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3.5. Circulating levels of soluble factors sCD23 and CD30 in HIV-associated NHL 
Soluble factors CD23 and CD30 were assayed by ELISA as it has been previously reported 
that they may play a role in B-cell malignancy in HIV positive patients 
(84, 112). 
CD23 is a low 
affinity receptor for IgE and is expressed on resting mature B-cells as a differentiation and/or 
early activation marker 
(139, 140)
. Soluble CD30 is a known marker of chronic B-cell 
stimulation and proliferation possibly leading to lymphoma 
(144-146)
.  
 
Our results showed that the plasma levels of sCD23 (median concentrations 1.972 vs. 1.583 
U/ml, respectively, p= 0.0759) and sCD30 (median concentrations, 23.14 vs. 10.67 U/ml 
respectively, p= 0.2045) were elevated in HIV positive patients with NHL cases compared to 
the HIV positive controls, however these results were not statistically significant (Figure 3.8). 
 
 
 
 
 
 
 
 
 
Figure 3.8: Soluble Factor expression in HIV-associated NHL. (A) sCD23 and B) sCD30 
were elevated in HIV positive patients with NHL but were not statistically different to 
controls (p= 0.0795 and p= 0.2045 respectively). 
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3.6.  In vitro cell culture of HIV-associated NHL 
In order to determine the effects of various B-cell stimulatory biomarkers on a lymphoma cell 
culture, PBMCs from a confirmed HIV positive patient with BL were cultured for 24 hours in 
complete RPMI culture media supplemented with antibiotics and serum.  
Compared with a normal healthy control, the BL cells failed to successfully grow in culture 
and were not viable for further experimentation (data not shown). The remainder of the HIV-
associated NHL samples (n=2) were tested for viability using the PI live/dead flow cytometric 
assay prior to culture. The unstained normal control tested negative for PI and demonstrated a 
population of viable cells and a smaller population of non-viable cells (0.5%) (Figure 3.9a). 
Whereas the patient cells were positive for PI and demonstrated a larger population of non-
viable cells (31.5%). (Figure 3.9b). Furthermore, fewer number of cells were available for 
acquisition for the patient sample compared to the normal control (1200 vs. 3000 cells 
respectively). 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.9: Flow cytometric histograms of Propidium Iodide viability assay. A) A 
healthy sample showing exclusion of propidium iodide staining (0.5% dead cells). B) 
Patient sample showing cell death by inclusion of propidium iodide staining (31.5%).  
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CHAPTER 4.0 
DISCUSSION OF RESULTS 
 
4.1. General Background  
B-cell NHL is an AIDS defining condition 
(23)
. In South Africa, where HIV infected patients 
present late and with high levels of immune dysregulation , HIV associated NHL is less 
common than would be anticipated given the high prevalence of infection. This probably does 
not reflect the true incidence but rather is indicative of under diagnosis and under reporting, as 
well as the high mortality rates associated with this aggressive cancer. It becomes important to 
ascertain both the underlying pathogenesis and explore new biomarkers which may improve 
early detection of malignancy. 
 
A number of potential oncogenic mechanisms in HIV associated lymphoma have been 
described. These include immune dysregulation associated with CD4+ T cell depletion and 
aberrant cytokine production which may drive uncontrolled B-cell proliferation and ultimately, 
transformation 
(84, 86, 162)
. Studies in other settings have found that the levels of a number of 
different cytokines and other biomarkers are increased in the plasma or serum of patients with 
HIV-associated NHL, both prior to, and after, the diagnosis of the malignancy 
(17, 37, 108, 163)
. 
Some of these may show diagnostic utility and predict the development of lymphoma and 
others play a pathogenic role in B-cell transformation 
(84, 85)
.  Some of these markers include IL-
6, IL-10, soluble CD23, CD27, CD30, CD44, CXCL13, TNF, IFNγ, as well as serum free light 
chains 
(17, 112, 164)
. This study aimed to examine the levels of a select number of these markers in 
a South African HIV population. 
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4.2. Epidemiology of the study cohort 
Diffuse large B-cell lymphoma followed by Burkitt lymphoma were the most common HIV-
related NHL subtypes amongst this study cohort. This is consistent with data from both the 
Gauteng and Western Cape provinces of South Africa that reported increased numbers of the 
latter cases 
(32, 87)
. 
 
There was no gender bias in this cohort with almost equal male: female ratios. In developed 
countries, a male preponderance has been described and this may reflect the HIV epidemic in 
South Africa which affects more females than males 
(165, 166)
.  Most of the studies conducted on 
HIV-associated NHL in other settings, generally consisted of cohorts of men-who-have-sex-
with-men, whereas in South Africa, the major risk group is the heterosexual population 
(87)
. 
This may also reflect the male bias seen in HIV-associated NHL that has been described in 
developed countries and the different male: female ratio found in this study 
(28, 166)
. The median 
CD4 count was significantly lower (p<0.0001) in HIV–associated NHL cases at diagnosis 
compared with HIV positive controls. This deviates from the literature documenting higher 
CD4 counts in patients with HIV-related NHL from Sub-Saharan Africa (Table 3.2) 
(165)
. This 
may reflect previous reporting biases as patients who attend clinics regularly for ARV therapy 
may possibly undergo more regular screening for known complications of HIV infection, like 
lymphomas. HIV positive patients with DLBCL had a moderately higher CD4 counts 
compared to those patients with BL, intermediate lymphoma and unspecified NHL (p = 
0.8699). Both BL and DLBCL occur in immunocompetent as well as immunocompromised 
individuals and the literature supports that patients with BL generally present with higher 
CD4+ T cell counts (Table 3.2) 
(165, 167)
. Our results differ from the literature and could be a 
direct result of DLBCL being the most common subtype diagnosed within this cohort 
compared to BL, intermediate lymphoma and unspecified NHL cases. 
 
The HIV viral loads in the controls were considerably lower compared to the NHL cases given 
the fact that all the controls were on anti-retroviral and/or HAART treatment which normalizes 
the viral load at a level lower than detectable (Table 3.1). Clinical data points were also not 
available for all HIV positive patients with documented NHL, namely; CD4 counts, treatment 
status and viral load which could possibly skew the demographic data of this study. Patient 
clinical history prior to 2013 was not also available, hence making it difficult to establish what 
previous diseases or disease exposures the patient might have encountered which could have 
influenced the results (see Table 3.1).   
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4.3. Circulating biomarkers elevated in HIV positive patients with NHL 
We hypothesized that several B-cell stimulatory cytokines would be elevated in the plasma of 
HIV-associated NHL, driving the proliferation of B-cells towards the development of HIV-
associated NHL, as based on the findings of the literature 
(17, 98, 112, 168)
.  
IL-6 is mainly involved in the terminal differentiation of B-cells into plasma cells and enhances 
the survival of and IgG antibody secretion by plasma cells 
(169-171)
. It also enhances the growth 
of malignant and non-malignant B-cells in an autocrine manner 
(100)
. In this study, HIV positive 
patients with documented NHL demonstrated significantly elevated plasma levels of factor IL-
6 (Figure 3.4). This result is consistent with studies reporting increased IL-6 protein expression 
in plasma several years prior to the development of HIV-related NHL as well as in HIV 
positive individuals without lymphoma 
(83, 84, 112)
. The fact that IL-6 is significantly elevated in 
HIV-associated NHL cases suggests that IL-6 may be produced and/or up-regulated in excess 
by the malignant B-cells themselves, thereby supporting the growth and survival of the tumour 
(172) 
.  
IL-4 and IL-5 promote the proliferation and differentiation of mature B-cells and induce 
immunoglobulin class switching of differentiated antibody secreting plasma B-cells 
(92, 95)
. The 
median IL-4 plasma concentration was slightly increased in HIV positive patients with NHL 
compared to HIV positive controls; however this was not statistically significant (Figure 3.4). 
This deviated from the literature demonstrated by Flepisi et al. who showed significantly 
increased levels of IL-4 in HIV–related NHL patients within a South African cohort (120). The 
slight increase in IL-4 protein concentration levels may be attributed to it being secreted by TFH 
cells within the germinal centre 
(84)
, although IL-4 usually functions post germinal centre to 
induce class switching of plasma B-cells to IgE 
(94, 95)
. Furthermore, IL-4 also induces the 
proliferation, differentiation and antibody secretion of B-cells in the presence of co-stimulatory 
molecules CD40L and LPS 
(92, 93)
. This suggests that IL-4 requires additional help from the 
latter co-stimulatory molecule to exert its function in B-cells and contribute to 
lymphomagenesis. 
No significant differences were noted in the plasma concentrations of B-cell growth factor IL-5 
between HIV-associated NHL cases and controls (Figure 3.4). This result was similar to the 
literature, although the association between IL-5 and the development of HIV-associated NHL 
has not been fully elucidated in the literature. IL-5 also stimulates the maturation of CD40 
activated B-cells and IgG1 secretion in B-cells stimulated with LPS 
(92, 93)
. Our result indicates 
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that IL-5 may not contribute to the development or progression of the tumour burden in HIV-
associated NHL and may also require additional help from stimulatory molecules such as LPS. 
4.4. Immunoregulatory cytokine IL-10 was significantly elevated in HIV-associated NHL 
IL-10, an anti-inflammatory cytokine, is produced by Th2 CD4+ T cells, macrophages and B-
cells 
(173)
. It functions to suppress or inhibit pro-inflammatory responses of the immune 
system and promote humoral immunity including B-cell proliferation and differentiation 
(174-
176)
. It was hypothesized that IL-10 would be elevated in HIV-associated NHL as described in 
the literature. In this study, IL-10 was significantly higher in HIV positive patients with 
confirmed NHL cases compared to HIV positive controls without lymphoma (Figure3.5). The 
results are consistent with previous studies which have demonstrated increased levels of 
plasma IL-10 prior to the onset of HIV-related NHL acting as a prognostic marker for the risk 
of development of NHL 
(98, 99)
. Similarly to IL-6, IL-10 has also been increased in HIV 
infection 
(137)
. This suggests IL-10 serves as a growth factor for B-cell lymphomas in an 
autocrine manner 
(98)
. It also suggests that IL-10 is involved in the interplay between tumour 
cells, oncogenic viruses (like KSHV) and the HIV virus and HIV infection supporting the 
hypothesis that B-cell stimulatory molecules drives the transformation of B-cells into 
malignancy. 
 
4.5. Th1 cytokines were not implicated in HIV-associated NHL 
The majority of the inflammatory mediators such as IL-1β, IL-2, TNFα and IFNγ have been 
implicated in the pathogenesis and control of HIV-1 infection and viremia respectively 
(107, 
137)
. Granulocyte Macrophage-Colony stimulating factor  is an essential haematopoietic 
growth factor and immune modulator 
(161)
.
 
In this study, however, no differences in protein 
concentrations were noted between HIV positive patients with confirmed NHL cases 
compared to HIV positive controls without lymphoma for analytes: IL-2 and GM-CSF (Table 
3.3). These results indicate that mediators of inflammation and GM-CSF are not required for 
lymphomagenesis. Similarly, there were no differences in the protein concentration of IL-1β, 
TNFα and IFNγ between HIV-associated NHL and HIV positive controls in this study, which 
differed from the literature which reported elevated levels of TNFα and IFNγ in the serum 
and/or plasma in HIV-associated NHL 
(108, 112, 120, 177)
. It is not entirely clear why our results 
differ as TNFα reportedly stimulates the proliferation of B-cells and Ig secretion in HIV 
positive and HIV uninfected individuals 
(178)
. TNFα has also been shown to up-regulate the 
expression of IL-10, which in turn inhibits its pro-inflammatory effects 
(137)
.  
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IFNγ also has the capacity to induce Ig class switching in B-cells(131). IL-1β , IFNγ and TNFα 
are also Th1 dominant cytokines and their levels may be suppressed and/or inhibited by IL-
10, a regulatory cytokine 
(174, 179)
 or as a subsequent result of the reduced CD4+ T –cell count. 
 
4.6. IL-8, but not SDF-1α, was significantly elevated in HIV-associated NHL 
IL-8 is also a pluripotent neutrophil chemokine and an angiogenic pro-inflammatory 
chemokine that is secreted by and expressed on both normal and tumourigenic cells 
(115), 
and 
has been implicated in the progression and metastasis of tumours 
(115, 116)
. Numerous studies 
have demonstrated that IL-8 was in several AIDS-NHL cell lines and were also significantly 
expressed in patients with NHL with or without HIV 
(118-120)
. In this study, IL-8 was 
significantly elevated in HIV-associated NHL when compared to HIV positive controls 
(Figure3.6). This finding is in keeping with a similar study performed in a cohort of South 
African patients demonstrating increased levels of IL-8 in the plasma of HIV-associated NHL 
(120)
. IL-8 is also produced by tumour cells and acts in a paracrine on nearby cells in the tumour 
microenvironment to exert its function and support tumour growth, proliferation and metastasis 
(115)
. This indicates that IL-8 may play a supporting role in the progression of NHL itself, by 
recruiting neutrophils and macrophages to the tumour site which may be secreting additional 
cytokines and growth stimulants further enhancing tumour growth 
(115, 117)
.  IL-8 could possibly 
be produced by the tumour cells themselves increasing their levels in HIV-associated NHL and 
not in HIV controls without evidence of lymphoma, irrespective of the viral load. 
 
SDF-1α is a chemoattractant homing  haematopoietic stem cells, specifically B-cell and its 
precursors,  to the bone marrow microenviroment 
(114)
. In HIV infection, SDF-1α mediates the 
hyperprolifertaion of B-cells and shares a co-receptor or ligand with HIV, CXCR4, which has 
been shown to be highly expressed in haematological malignancies 
(121, 122)
. Although the 
median concentrations of SDF-1α were slightly higher in the plasma of HIV positive patients 
with NHL when compared to controls, these results were not significant (Figure 3.6). These 
results could also be attributed to the smaller sample size available for measurement (n=20), 
and a larger cohort of patients should be studied in the future. Because of its function as a 
homeostatic chemokine which condones trafficking of precursor B-cell and stem cells SDF-1α 
may be more permissive of tumours arising in earlier precursor stages of B-cell development in 
the bone marrow rather than more mature lymphomagenesis.  
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The majority of HIV-NHLs usually manifest at the germinal centre or post germinal centre 
maturation stages of B-cell development 
(1, 19)
. 
Taken together, these results how that elevated levels of cytokines IL-6, IL-8 and IL-10 may 
play a role in the pathogenesis of HIV-associated NHL, possibly through by stimulating and 
increasing the proliferation of B-cells in HIV positive patients with NHL. Furthermore, these 
cytokines are also implicated in the interplay between malignant cells and HIV infection. 
 
 
4.7. Correlations between cytokine levels of IL-6, IL-8 and IL-10 
It was hypothesized that the cytokine expression of IL-6 and IL-10 would be dependent on 
each other as numerous studies have reported that these two cytokines are able to up-regulate 
each other’s expression (83, 100, 106). In this study, no correlation was seen between IL-6 and IL-
8 or between IL-8 and IL-10 (Figure 3.7) for HIV-associated NHL cases. IL-8 is expressed by 
various cells types, including tumour cells, within the tumour microenvironment and usually 
exerts its function in a paracrine manner 
(115, 117)
. Whereas IL-6 and IL-10 are produced by the 
malignant B-cells in an autocrine manner as well as by monocytes 
(99, 100)
. This confirms that 
IL-8 is expressed independently of IL-6 and IL-10 and does not function with these cytokines 
to promote tumour growth. The negative correlation observed between IL-8 and IL-10 further 
suggests IL-8 is autonomous in its role in tumorigenesis. This is supported by its main 
function as a neutrophilic chemokine and a pro-angiogenic cytokine 
(115, 116)
. 
 
A correlation was noted between cytokine concentration levels of IL-6 and IL-10. Both of 
these cytokines are produced by B-cells in an autocrine manner suggesting that they may be 
working together synergistically to enhance B-cell transformation 
(98, 100)
. IL-6 and IL-10 have 
also been reported to be increased in HIV-1 infection 
(137)
. This suggests that their increased 
expression is attributed by both HIV and the tumour B-cells and theses cytokines may in turn 
function together to enhance B-cell growth. 
 
4.8. Soluble factors exhibit an increased trend in HIV-associated NHL 
sCD23 is a differentiation and/or early activation marker of mature B-cells and mediates Ig 
isotype class switching 
(139, 140)
. sCD30 is a known marker of chronic B-cell stimulant and may 
play a role in B-cell proliferation 
(144)
. In this study, we hypothesized that both soluble CD23 
and CD30 would have increased expression in HIV positive patients with NHL as reported in 
the literature 
(84, 144, 152, 180)
. We found that both sCD23 and sCD30 (Figure 3.8) displayed an 
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elevated trend in HIV-associated NHL cases compared to controls, although these results were 
not statistically significant.   
These results were similar to other studies conducted on sCD23 and sCD30 in relation to HIV-
associated NHL. Yawetz et al. showed that sCD23 levels were elevated in patients who 
developed AIDS- associated NHL compared with patients who had AIDS without lymphoma 
as well as HIV sero-negative and positive patients 
(141)
. Schroeder et al. likewise showed 
elevated levels of sCD23 in AIDS-associated NHL in the absence of gamma herpesvirus EBV 
(152)
 
(84)
. 
In this study, sCD30 demonstrated an increase trend in HIV positive patients compared to HIV 
positive controls without lymphoma. Purdue et al. and Breen et al. both reported elevated 
circulating levels of sCD30 in HIV positive individuals who developed NHL as a pre-
diagnostic marker of HIV associated NHL
(144, 163)
. These results may suggest that both of these 
markers have potential as diagnostic screening markers for patients with HIV-associated NHL. 
This would need to be validated in a larger cohort. 
 
4.9. Cell culture of HIV-associated NHL  
To investigate the effects of B-cell stimulatory biomarkers on lymphomagenesis, an in vitro 
culture of lymphoma cells from a BL patient was made. We hypothesized that HIV-associated 
NHL would grow vigorously in culture as it has a high rate of proliferation 
(44, 45, 49)
. Burkitt 
lymphoma has a high proliferation rate with a Ki-67 index of nearly 100% and is characterised 
by high cellular turnover 
(43, 44)
. The cells, however, failed to grow successfully in culture and 
were not viable for further testing when compared to a normal healthy control (Figure 3.9). 
Studies on establishing in vitro cultures of lymphoma cells generally used cells isolated from 
the lymph node or the primary source of the tumour burden 
(181, 182)
,  whereas the cells use for 
this study were isolated from peripheral blood. This suggests that these cells grow better when 
in a suitable microenvironment or specific niche which stimulates their growth in vivo. As the 
cells that we were trying to culture were isolated from peripheral blood and not the lymph 
node, this may have impacted on the survival of these cells. It was suggested that additional 
growth factors and/or mitogens be added to the culture to enhance B-cell growth in vitro. CD40 
has been reported to be an efficient stimulant to facilitate the growth of malignant B-cells in 
vitro 
(183)
. Pokeweed mitogen has also been shown to stimulate the proliferation of lymphocytes 
in culture 
(184)
. Unfortunately, we did not have enough material to culture with these additional 
growth factors to test this theory, but this would be worth exploring in future studies. 
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4.10. Other factors impacting the results of this study 
Various factors may explain the discrepancies between this study and the published literature. 
The differences in the geographical subtypes of HIV-1 between published literature and this 
current study may also have affected the outcome of these results. In high income countries in 
Europe, the United States and Japan, Clade B is the dominant HIV subtype, whereas Clades A, 
C, D and E are most common subtypes in low and middle income countries (reference). HIV-1 
Clade C is the predominant subtype in Sub-Saharan Africa, India and Brazil, whereas Clade A 
is predominant in Eastern Europe and Northern Asia 
(185-187)
. Most studies in the literature focus 
on subtypes A and B, whereas subtype C is the predominant subtype in South Africa 
(185, 187)
. In 
addition, the majority of the published literature measured these biomarkers retrospectively in 
stored serum of patients several years prior to diagnosis 
(37, 86, 164)
, whereas in this study the 
biomarkers were assessed prospectively in the plasma of patients recently diagnosed with 
lymphoma prior to commencement of treatment.  
 
CHAPTER 5.0 
LIMITATIONS AND SHORT COMINGS 
This study had a few limitations. Not all clinical information could be accessed for all patients. 
Some patients were lost to follow-up or died prior to intensive investigation. Plasma from all 
patients could not be assessed for SDF-1α due to insufficient residual plasma sample. It is 
possible that, had the numbers of patients assessed been higher, these results would have 
differed significantly as shown in other work. Finally, a small number of patients had to be 
excluded from the final analysis after concomitant chronic conditions (most notably 
tuberculosis) were diagnosed. Although the patients in this cohort did not have detectable 
tuberculosis disease, the impact of latent tuberculosis infection on the biomarkers measured in 
this study was uncertain. It would be valuable, however, to ascertain the rates of infection with 
Mycobacterium tuberculosis occurring in patients with HIV-associated lymphoma as it is 
possible that this infection may be a secondary driver of the malignant process. Patients were 
not assessed for concomitant viral infections (like EBV and KSHV) but it is likely from the 
known association between viral infections and lymphoma that the majority had previous or 
on-going gamma herpesviridae infections. 
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CHAPTER 6.0. 
CONCLUSION & OUTLOOK 
In summary IL-6, -8 and -10 were identified as significantly elevated in HIV-associated NHL 
cases when compared to HIV positive controls without lymphoma. Soluble factors CD23 and 
CD30 exhibited a trend towards increased expression in HIV positive patients with documented 
lymphoma. Future work would include repeat Luminex and ELISA assays with increased 
numbers of samples as well as comparing these results to an additional cohort of HIV 
uninfected patients. Cell culture experiments need to be repeated with additional stimulants to 
enhance B-cell growth. This study has demonstrated the link between elevated levels of B-cell 
stimulatory cytokines IL-6, -8 and -10 which may contribute to the pathogenesis of HIV-
associated NHL in a South African cohort. These cytokines may serve as a valuable therapeutic 
strategy by suppressing or neutralizing its expression within the tumour microenvironment in 
HIV-associated NHL thereby inhibiting tumour progression, growth and/or transformation of 
malignant B-cells. Alternatively, they can also serve as a diagnostic screening marker and 
could be included in the current flow cytometry immunophenotyping panel. 
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APPENDIX A 
 
 
  
Figure 1: Printout of ethics clearance certificate 
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TURNITIN REPORT 
  
Figure 2: Turnitin Report 
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Table 1:  A description of B-cell stimulatory molecules and there function in relation to 
B-cell lymphomas 
B-cell stimulatory molecules Function related to B-lymphocytes and B-cell 
lymphomas 
 
Serum/Plasma Cytokines 
 
Interleukin-6  IL-6 is produced by malignant cells and contributes 
significantly to  proliferation 
(100)
 
 Anti-apoptotic marker for B-cells and may act as a 
growth factor for HIV-associated lymphoma cells in 
vitro 
(83) 
 
Interleukin-10  Anti-apoptotic marker for B-cells and may act as a 
growth factor for HIV-associated lymphoma cells in 
vitro
(83)
 Autocrine B-cell growth factor for B-cell 
lymphomas 
(98)
 
 Genetic properties,  SNP within the promoter region of 
IL-10 gene, are related to development of AIDS-
associated lymphoma and NHL 
(79)
 
 In vivo production of IL-10 may stimulate proliferation 
of malignant cells in an autocrine fashion. Its 
production is triggered synergistically by HIV and EBV 
(99)
 
Interleukin-4  Involved in the growth and survival of Non-Hodgkin B-
lymphoma cells in vitro. 
 Regulates proliferation and maturation of B-cells (38) 
 Induces class switching to IgG1, G4 and IgE 
Interleukin-5  Promotes cell differentiation and survival of B-cells 
 Stimulates the maturation of CD40 activated B-cells to 
IgM and IgG1 secreting cells 
Interleukin-13 
 
 
 Involved in the growth and survival of non-Hodgkin’s 
B-lymphoma cells in vitro.  
 Regulates proliferation and maturation of B-cells (38) 
CD40 Ligand  Elicits  activation and proliferation of B-cells 
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TNFα  Acts as a co-stimulant promoting B-cell differentiation 
induced by CD40L and IL-4 
(94, 134)
 
 Has the capacity to stimulate B-cell  proliferation and 
the production of IgG by B-cells and associated with 
inflammation 
(84)
 
 Salles et al reported that elevated plasma levels  in 
lymphoma patients , is associated with disease 
aggression and may predict the outcome of the patient 
(188)
 
TNF ß  Commonly referred to as lymphotoxin (84) 
IFNγ  Promotes survival and differentiation of B-cells 
 Inhibits CD40L B-cell proliferation and IL-4 IgE class 
switching 
 
Chemokines 
 
CXCL13  Homeostatic B-cell chemokine also referred to as a B-
lymphocyte chemo-attractant 
(84) 
 Produced by T follicular helper cells and  follicular 
dendritic cells 
 Attracts B-cells to secondary lymphoid organs (17) 
CXCR5  Also known as Burkitt lymphoma receptor 1 (BCR1)  
 Expressed on mature B-cells and subsets of T cells 
 Receptor for CXCL13 (84) 
 Together with its ligand CXCL13, these chemokines 
guide B-cells towards secondary lymphoid organs  
  Single nucleotide polymorphisms associated with risk 
of NHL  
 Several polymorphisms has been reported to be 
associated with risk of NHL 
(189)
 
Soluble factors   
sCD23  Expressed on mature resting B-cells 
 Acts as a B-cell growth factor (190) 
 Up-regulates the production of monocyte IL-6 (180)  
sCD27  Members of the tumour necrosis factor receptor 
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superfamily 
(84)
 
 Expressed primarily on T cells but also on B and NK 
cells 
 Various types of malignancies also express CD27  and 
has apparent correlation to the tumour load, suggesting 
the tumour itself may possibly be a source of sCD27 
(191)
 
sCD30  Members of the tumour necrosis factor receptor 
superfamily  
 Marker of chronic B-cell stimulation which may be 
involved in B-cell proliferation that could lead to 
genetic error accumulations and possibly cause 
lymphoma 
(144)
 
sCD44  Elevated preceding diagnosis of NHL and thus may be 
an indicator of immune dysregulation preceding AIDS-
NHL diagnosis 
(79) 
 Elevated following NHL, suggesting it may be a by-
product of the tumour cells  
Other  molecules associated 
with immune system 
activation and inflammation 
 
Free immunoglobulin light 
chains (FLC) 
 Possibly biomarkers of polyclonal B-cell activation 
and dysfunction as well as  risk of developing NHL in 
an HIV setting 
(192)
 
CRP  Surrogate biomarker for IL-6 and other inflammatory 
cytokines 
(193)
 
 Acute phase protein (86)  
Page | 53  
 
APPENDIX B 
Reagent preparations and standard concentrations 
 
Table 2: Human cytokine 10-plex panel: Cytokine analytes and their respective 
standard concentrations 
Cytokine analyte Reconstituted standard 
concentration pg/ml 
(provided by package 
insert) 
IL-1β 8,150 
IL-2 10,200 
IL-4 36,300 
IL-5 9,100 
IL-6 5,850 
IL-8 13,450 
IL-10 20,850 
GM-CSF 22,450 
IFNϓ 9,550 
TNFα 8,850 
 
Table 3: Human cytokine 10-plex panel reagent preparation indicating the appropriate 
dilution factor and volumes 
Reagent Dilution 
factor 
Volumes (µl) 
Human 16-plex Standards (1-7) 3-fold serial 
dilution 
150ul of assay diluent and  
450ul reconstituted standard 
Plasma samples of HIV associated 
NHL and HIV positive individuals 
without evidence of overt lymphoma 
2-fold 50µl of plasma sample and 
50µl of assay diluent 
Human cytokine 10-plex Antibody 
bead concentrate (20x) 0.25ml 
1:11 220µl of Antibody mix was 
diluted with 2.2ml of wash 
solution 
Human cytokine 10-plex Biotinylated 1:11 880µl of Antibody concentrate 
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Antibody concentrate (10x) 1ml was diluted in 8.8ml of Biotin 
Diluent 
Wash Solution Concentrate (20x) 
15ml 
1:20 285ml of distilled water  
(dH2O) to 15ml of wash 
solution 
Streptavidin-RPE Concentrate (10X) 
1ml 
1:11 880µl of Strep-PE concentrate 
was diluted in 8.8ml of 
Streptavidin-PE Diluent 
 
Table 4: Standard concentrations of the SDF-1α Luminex and ELISA assays 
 
 
 
 
 
 
 
 
 
Table 5: Reagent preparation including the dilution factor and volumes for sCD30 
ELISA kit 
Reagent Dilution Factor Volumes 
Plasma sample 1:4 25 µl of sample + 75 µl of 
sample diluent 
Standards 1:2 100µl of sample diluent + 
100µl of standard 
HRP-Conjugate, anti-sCD30 
monoclonal (murine) 
1:100 60µl of conjugate diluted in 
5.94ml of assay buffer 
Kit Number of 
standards/ 
controls 
Reconstituted standard 
concentration pg/ml 
(provided by package 
insert) 
Human SDF-1α 
Simplex 
7 standards 73,500-17.944pg/ml 
sCD23 EASIA 
ELISA 
6 standards 0.00-20.0U/ml 
sCD23 EASIA 
ELISA 
2 controls Control 1: 2.410U/ml 
Control 2: 9.32.3U/ml 
sCD30 ELISA 7 standards 100-1.6U/ml 
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antibody. 
Wash Buffer 
Concentrate(20x) (PBS with 
1% Tween 20) 
1:20 50ml of wash buffer added to 
950ml of dH2O 
Assay Buffer Concentrate 
(20x) (PBS with 1% Tween 
20 and 10% BSA) 
1:20 5ml of assay buffer diluted in 
95ml of dH2O 
 
Table 6: Reagent preparation including the dilution factor and volumes for sCD23 
EASIA ELISA kit 
 
 
 
 
 
 
 
 
 
  
  
Reagent Volumes 
Plasma samples and 
standards 
100 µl diluent + 100 µ l 
standards or samples (1:2) 
Diluent  Add 8ml  of dH2O 
Controls 1& 2 in human 
plasma with preservatives 
Add 1ml of dH2O 
Washing Solution 
Concentrate (buffer with 
preservatives) 
Add 2ml in 400ml of dH2O 
Concentrated Chromogenic 
TMB solution 
Add 0.2ml into 1 vial of 
Substrate buffer 
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APPENDIX C 
Cell culture calculations 
Total cell count and viability using the Neubauer counting chamber and trypan blue dye 
(example) 
Dilution factor= 2 
Average Number of Live cells (n) = 34.375 cells/ml 
Average number of dead cells (n) = 3 cells/ml 
Total number of cells (n) = 35.75 
#Cells/ml= Average # cells x dilution factor x 10
4 
= 34.372 x 2 x10
4
 
 = 6.872 x 10
6
 cells/ml 
 
Cell viability = Average # live cells/ Average # total cells x 100 
                      = 34.372x 100 
                          35.75 
                      = 96% 
 
To resuspended cells at a concentration of 1 x 10
6
 cells/ml in 2ml of culture media 
C1V1= C2V2 
6.872 X 10
6
 X 2ml = 1 x10
6
 V2 
= 13.744ml 
 
13.744-2ml= 11.74 ml of culture media 
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APPENDIX D 
Antibody titration tables and graphs 
 
Table 7: Mean Fluorescence Intensity values for antibody titration of CD19 PE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ancestry Subset Statistic for 
Lymphocytes (MAb volumes µl) 
MFI 
CD19 PE 
Unstained control n/a 
2µl CD19 4213 
5µl CD19 5198 
10µl CD19 6016 
15µl CD19 5800 
CD19 Antibody Titration
0 2 5 10 15
0
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2000
3000
4000
5000
6000
7000
Volume of Ab (l)
M
F
I
CD19 PE Antibody Titration 
Figure 3: CD19 PE Antibody Titration. MFI plotted against the volume of MAb (µl) to 
determine the optimal amount of MAb to use for flow cytometry experimentation. 
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Table 8: Mean Fluorescence Intensity values for antibody titration of CD38 APC 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 4: CD38 APC Antibody titration: MFI plotted against the volume of MAb (µl) to 
determine the optimal amount of MAb to use for flow cytometry experimentation. 
 
 
 
 
 
Ancestry Subset Statistic for 
Lymphocytes (MAb volumes 
µl) 
MFI 
CD38 APC 
Unstained control n/a 
2 6427 
5 6955 
10 6760 
15 6817 
CD38 Antibody Titration
0 2 5 10 15
0
1000
2000
3000
4000
5000
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M
F
I
CD38 APC Antibody Titration 
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Table 9: Mean Fluorescent Intensity values for antibody titration of CD3 FITC 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 5: CD3 FITC Antibody titration. MFI plotted against the volume of MAb (µl) to 
determine the optimal amount of MAb to use for flow cytometry experimentation. 
 
 
 
 
 
Ancestry Subset Statistic for 
Lymphocytes (MAb volumes 
µl) 
MFI 
CD3 FITC 
Unstained control n/a 
2 18874 
5 19534 
10 20329 
15 20972 
CD3 Antibody Titration
0 2 5 10 15
0
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Volume of Ab (l)
M
F
I
CD3 FITC Antibody Titration 
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Table 10: Mean Fluorescent Intensity values for antibody titration of CD4 PE 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Ancestry Subset Statistic for 
Lymphocytes (MAb volumes 
µl) 
MFI 
CD4 PE 
Unstained control n/a 
2 15862 
5 17535 
10 17390 
15 17666 
CD4 Antibody Titration
0 2 5 10 15
0
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4000
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10000
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14000
16000
18000
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M
F
I
CD4 PE Antibody Titration 
Figure 6: CD4 PE Antibody titration. MFI plotted against the volume of MAb (µl) to 
determine the optimal amount of MAb to use for flow cytometry experimentation. 
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Table 11: Mean Fluorescent Intensity values for antibody titration of CD8 Alexa Fluor® 
700 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 7: CD8 AlexaFluor® 700 Antibody titration. MFI plotted against the volume of 
MAb (µl) to determine the optimal amount of MAb to use for flow cytometry 
experimentation. 
 
  
Ancestry Subset Statistic 
for Lymphocytes (MAb 
volumes µl) 
MFI 
CD8 Alexa Fluor® 700 
Unstained control n/a 
2 4824 
5 4650 
10 4800 
15 4891 
CD8 Antibody Titration
0 2 5 10 15
0
1000
2000
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M
F
I
CD8 AlexaFluor® 700 Titration 
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APPENDIX E 
 
Table 12: A comprehensive list of MAb panel used to perform antibody titration and 
set-up of multi-colour compensation 
Monoclonal 
Antibody 
Fluorescent 
marker 
Supplier 
Anti-human CD19 PE eBioscience, US 
Anti-human CD3 FITC eBioscience, US 
Anti-human CD4 PE eBioscience, US 
Anti-human CD8 Alexa Fluor® 
700 
BioLegend, CA, 
US 
Anti-human CD38 APC eBioscience, US 
Anti-human Ki-67 Alexa Fluor® 
647 
BioLegend, CA, 
US 
Isotype control 
IgG1 ĸ (Mouse) 
APC 
PE 
FITC 
eBioscience, US 
 
Isotype control 
IgG1 ĸ (Mouse) 
Alexa Fluor® 
700 
Alexa Fluor® 
647 
 
BioLegend, CA, 
US 
 
 
Flow cytometry experiments 
 
Table 13: Experimental layout for flow cytometry assay  
 
Experiment Layout Volume of MAb 
(µl)Fluorescent 
marker 
Function 
Tube 1: CD19 PE 
             CD38 APC 
10 
5 
To determine the percentage 
of activated  f B-cells 
Tube 2: CD3 FITC 
             CD4 PE 
6 
5 
To determine the percentage 
of activated T-cells 
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             CD8 AlexaFluor® 
700 
             CD38 APC 
5 
5 
Tube 3: CD19 PE 
Ki-67AlexaFluor® 647 
5 
10 
To determine the percentage 
of proliferating B-cells 
Tube 4: CD3 FITC 
             CD4 PE 
             CD8 AlexaFluor® 
700     
Ki-67AlexaFluor® 647 
6 
5 
5 
5 
To determine the percentage 
of proliferating T-cells 
Tube 4: Isotype Control 
IgG1ĸ (Mouse) 
FITC 
APC 
PE 
AlexaFluor® 700 
 
5 µl of each 
antibody 
Negative control 
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APPENDIX F 
 
Instrument Calibration 
1. Calibration of the LSR II Flow cytometer 
The LSRII Flow cytometer (BD Biosciences, USA) was calibrated daily and weekly in 
accordance with the manufacturers and the laboratory’s requirements to monitor performance 
of the optics and fluidics systems. The SPHERO Rainbow Single Peak calibration beads (BD 
Biosciences, USA) were used daily and the cytometer set-up and tracking beads (CST) (BD-
Biosciences, USA) weekly to calibrate the LSRII.  . 
The Sphero single beads ensured that fluorescent peaks for each fluorescent parameter were 
within the H gate and the voltages adjusted where necessary in order to align the fluorescent 
peak within the H gate (appendix E). The CST beads verified the properties of the violet, red 
and blue lasers by measuring the coefficient of variation (CV) for each laser.  
  
Figure 8: Snapshot of the daily QC SPHERO Rainbow Single Peak 
calibration beads.  
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2. Colour compensation setup on the LSRII  flow cytometer 
Multi-colour compensation was carried out to remove and correct for any background signal 
and spill over between different fluorochomes 
(194)
. Colour compensation was performed 
using BD™ CompBeads negative control beads and BD™ CompBeads Anti-Mouse Igκ 
positive capture beads (BD-Biosciences, USA).The latter binds to any Ig bearing the mouse 
kappa light chain, while the negative control has no binding capacity, providing distinct 
positive and negative stained populations 
(195, 196)
. An unstained control was used to adjust the 
forward scatter (FSC) and side scatter (SSC), and six single stained monoclonal antibody 
(MAb) tubes were used to adjust fluorophore photomultiplier tubes PMT voltages. A 
minimum of 5000 events were recorded for each MAb. Compensation was calculated and 
applied to all experimental tubes.  
3. Calibration of the Bio-Rad Luminex200 
The Bio-Rad 200 Luminex xMAP™ (Bio-Rad Laboratories Inc., USA) was appropriately 
calibrated and maintenance was done to monitor the laser and instrument performance before 
use. The lasers were warmed up automatically using the xPONENT 3.1 software (Luminex 
Corporation, Austin, Texas) before calibration was performed. 
 An initialization step ran which included a prime to remove any trapped bubbles in the 
system and two alcohol flushes. The instrument was then calibrated by running the following 
calibration control beads in a 96 well plate: CAL1, MagCAL1, CAL2, CON1, MagCON1 and 
CON2 (Luminex Corporation, Austin, Texas). 
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APPENDIX G 
 
Standard Curves  
 
 
 
 
  
Figure 9: Human 10-plex cytokine panel 5-parameter logistic standard curves. A) IL-
1β, B) IL-2, C) IL-4 and D) IL-5. Concentrations (pg/ml) were plotted against the mean 
fluorescence intensity (mfi) using Luminex Technology. 
 
A 
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B 
Page | 67  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Human 10-plex cytokine panel 5-parameter logistic standard curves. A) IL-6, 
B) IL-8, C) IL-10 and D) TNFα.  
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Figure 11: sCD23 4-parameter logistic standard curve. The standard curve was generated 
automatically using the Adaltis™ Easy Interface software. Concentrations (U/ml) were 
plotted against the optical density (absorbance 450nm). 
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Figure 12: sCD30 4-parameter logistic standard curve. 
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